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SUMMARY 
Percutaneous coronary intervention (PCI) is the current procedure that allows the 
endovascular treatment of occlusive artery disease, without the need of bypass 
surgery. The most problematic complication of PCI, with or without stent 
implantation, is the restenosis defined as the re-narrowing of the enlarged artery 
and characterized by an immune/inflammatory response going with a hyperplastic 
reaction, involving smooth muscle cell (SMC) migration/proliferation, and 
remodelling of the arterial wall. In an effort to improve on current therapy for 
restenosis we are prompted to consider new strategies for prevention and 
treatment, focusing on understanding of molecular mechanisms and identifying 
possible therapeutic targets. This thesis aims at four issues described as follows: 
 
1. Effect of NBD peptide on injury-induced neointimal formation  
The activation of nuclear factor-κB (NF-κB) is a crucial step in the arterial wall's 
response to injury. NF-κB essential modulator-binding domain (NBD) peptide blocks 
the activation of the IκB kinase complex, selectively abrogating the inflammation-
induced activation of NF-κB. In this study, we investigated the effect of NBD peptide 
on neointimal formation using two animal models of arterial injury: rat carotid artery 
balloon angioplasty and wire-induced carotid injury in apolipoproteinE-deficient 
(apoE-/-) mice.  
Local treatment with the NBD peptide (300 μg/site) significantly reduced the number 
of proliferating cells in rat carotid arteries 7 days after angioplasty (by 40%; P<0.01) 
and reduced injury-induced neointimal formation (by 50%; P<0.01) at day 14. These 
effects were associated with a significant reduction of NF-κB activation and 
monocyte chemotactic protein-1 (MCP-1) expression in the carotid arteries of rats 
treated with the peptide. In addition, the NBD peptide (0.01 to 1 μM) reduced rat 
SMC proliferation, migration, and invasion in vitro, processes contributing to the 
injury-induced neointimal formation in vivo. Similar results were observed in apoE-/- 
mice in which the NBD peptide (150 μg/site) reduced wire-induced neointimal 
formation at day 28 (by 47%; P<0.01). 
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Our results demonstrate that the NBD peptide reduces neointimal formation and 
SMC proliferation/migration, both effects associated with the inhibition of NF-κB 
activation. 
 
2. Use of the anti-inflammatory agent bindarit to control neointimal 
hyperplasia  
Chemokines are a family of proteins that regulate the migration of circulating 
leukocytes to sites of arterial injury as well as the activation of SMCs. Many 
chemokine genes are under the control of NF-κB. Bindarit is an original compound 
with peculiar anti-inflammatory activity due to a selective inhibition of the 
chemokines MCP-1, MCP-3, and MCP-2. In the present study we evaluated the 
effect of bindarit on neointimal formation using both animal models described 
above. 
Treatment of rats with bindarit (200 mg/kg/day) significantly reduced balloon injury-
induced neointimal formation by 39% at day 14 without affecting re-
endothelialisation and reduced the number of medial and neointimal proliferating 
cells at day 7 by 54% and 30%, respectively. These effects were associated with a 
significant reduction of MCP-1 levels both in sera and in injured carotid arteries of 
rats treated with bindarit. In addition, in vitro data showed that bindarit (10-300 µM) 
reduced rat SMC proliferation, migration, and invasion. Similar results were 
observed in apoE-/- mice in which bindarit administration resulted in a 42% reduction 
of the number of proliferating cells at day 7 after carotid injury and in a 47% 
inhibition of neointimal formation at day 28. Analysis of the cellular composition in 
neointimal lesions of apoE-/- mice treated with bindarit showed that the relative 
content of macrophages and the number of SMCs were reduced by 66% and 30%, 
respectively, compared with the control group. 
This study demonstrates that bindarit is effective in reducing neointimal formation in 
both non-hyperlipidaemic and hyperlipidaemic animal models of vascular injury by a 
direct effect on SMC proliferation and migration and by reducing neointimal 
macrophage content. All of these data were associated with the inhibition of MCP-1 
production. 
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3. Role of Monocyte Chemotactic Protein-3 in human coronary smooth 
muscle cell proliferation  
Few studies have examined the role of MCP-3 in vascular pathologies such as 
atherosclerosis and restenosis in which SMC proliferation plays an important role. In 
this study, we investigated the effect of MCP-3 on human coronary artery SMC 
(CASMC) proliferation.  
MCP-3 induced concentration-dependent CASMC proliferation with the maximum 
stimulatory effect at 0.3 ng/mL (about 50% vs unstimulated cells) assessed by 
bromodeoxyuridine (BrdU) uptake and direct cell counting. Anti-MCP-3 Ab (20 
ng/mL) completely inhibited cell proliferation, demonstrating the specificity of the 
proliferative effect of MCP-3. Moreover, the MCP-3-induced CASMC proliferation 
was blocked by RS 102895 (0.06-6 μM), a specific antagonist of chemokine 
receptor 2 (CCR2). The mitogenic effect of MCP-3 appeared to be dependent on 
ERK1/2 MAPK and PI3K signalling pathway activation, as demonstrated by the 
reduction of MCP-3-induced CASMC proliferation observed after the treatment of 
cells with U0126 (1 μM) and LY-294002 (5μM), selective inhibitors of ERK 1/2 and 
PI3K activation, respectively. We found no relationship between MCP-3-induced 
CASMC proliferation and NF-κB activation. Moreover, we found that tumor necrosis 
factor-α (TNF-α, 30 ng/mL) and interleukin-1β (IL-1β, 1 ng/mL) both induced time-
dependent increase of MCP-3 production by CASMCs, which was reduced by the 
anti-MCP-3 Ab (20 ng/mL), suggesting that the mitogenic effect of these stimuli is 
due, at least in part, to MCP-3.  
Our results demonstrate that MCP-3 is produced by human CASMCs and directly 
induces CASMC proliferation in vitro, suggesting a potential role for this chemokine 
in vascular pathology. 
 
4. Antigen presentation and costimulatory molecules expression by murine 
smooth muscle cells  
The findings that SMCs express MHC II molecules during arterial response to injury 
suggested their active role in cellular immunity. Since it is not known if vascular 
SMCs can function as antigen presenting cells, in the present study we investigated 
the contribution of SMC in antigen presentation.  
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Firstly, we examined the MHC II and some costimulatory molecules expression in 
SMCs. The percentage of MHC II, CD54 (ICAM-1), CD44 and OX40L positive 
unstimulated SMCs was about 2%, 30%, 87% and 5%, respectively. The stimulation 
with IFN-γ (100 ng/mL)) significantly caused a 7 to 8 fold increase in the percentage 
of MHC II positive cells (P<0.01), a 2 fold increase in the percentage of ICAM-1 
positive cells (P<0.01), while it did not affect the expression of CD44 and OX40L. 
To assess the antigen presentation by SMCs we employed the Ealpha (Eα)-GFP/Y-
Ae system that allows visualisation of antigen uptake, as the Eα is GFP labelled, 
and tracking of antigen presentation using the Y-Ae Ab to detects Eα when bound 
to MHC II. Treatment of SMCs with Eα for 24 h induced an increase in the 
percentage of GFP positive cells, both in presence or absence of IFN-γ-stimulation, 
without affecting the percentage of Y-Ae positive cells. Treatment with Eα of 
dendritic cells, used as positive control, significantly caused a 50 to 60 fold increase 
in the percentage of both GFP and Y-Ae positive cells. Our results show that 
cultured murine SMCs express MHC II molecules after stimulation with IFN-γ but 
are not able to present the antigen in the context of MHC II.  
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1. INTRODUCTION 
 
Cardiovascular diseases (CVDs) are the leading causes of death and 
disability in the world, claiming 17.3 million lives a year. This fact forces us to 
consider new strategies for prediction, prevention, and treatment. 
The prevalent type of CVDs in western societies is the coronary artery 
disease, in which an artery wall thickens because of the deposition of 
atherosclerotic plaque triggered by LDL accumulation within the artery wall. At the 
base of atherosclerosis there is an inflammatory process with an immune 
component depending on the interaction of multiple cellular populations of the 
peripheral blood, mainly monocytes and T lymphocytes, with cell components of the 
arterial wall, mostly endothelial and smooth muscle cells (SMCs), in response to 
multifactorial vascular injury (Hansson and Jonasson, 2009). This interaction results 
in the stenosis of the coronary vessels and may range from asymptomatic to 
angina, or to myocardial infarction. 
The current procedure that allows the endovascular treatment of occlusive 
coronary artery disease, without the need of bypass surgery, is the percutaneous 
coronary intervention, commonly known as angioplasty. This procedure is executed 
by attaching a small balloon to a catheter. Once inflated on the stenosis, the balloon 
dilates the artery and improves blood flow (balloon angioplasty, Fig. 1.1).  
The most problematic complication of percutaneous coronary intervention is 
a well known process called restenosis, defined as the re-narrowing of the artery 
after initial angioplastic treatment, identifiable by a lumen diameter diagnosis of 
<50% at follow-up (Fig 1.1).  
 
1.1 Restenosis 
The restenosis was proposed to be the arterial wall‘s healing response to 
mechanical injury consisting of platelet aggregation, inflammatory and immune cell 
infiltration, release of growth factors, SMC proliferation, collagen deposition and 
extracellular matrix (ECM) rearrangement. All these events contribute to the two 
major processes of restenosis following the angioplasty, intimal hyperplasia and 
vessel remodelling. 
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Between 1980s and 1990s coronary stenting strategies have been 
developed, in an effort to improve the outcome of angioplasty. They consist in metal 
mesh tubes, called stents, placed during percutaneous coronary intervention inside 
the artery to keep it open, thus preventing acute occlusion and restenosis (Fig. 1.1). 
Stents implantation initially appeared promising but after their introduction it became 
apparent that the late in-stent restenosis was one of the major drawbacks after 
successful revascularization, with restenosis rate ranging from 15% to 60%  at six 
months depending on lesion morphology and other factors (Elezi et al., 1998) (Fig. 
1.1). 
The central pathogenetic events of in-stent restenosis are the recruitment of 
inflammatory cells to the site of injury and the migration of vascular SMCs from the 
tunica media through the disruption of endothelial barrier following the mechanical 
stretch. There, the SMCs proliferate actively giving rise to the neointima, which in 
turn obstructs the vessel (Costa and Simon, 2005).  
In order to prevent the in-stent restenosis, recent technology has created the 
drug-eluting stents (DES): using a coronary stent for local delivery of drugs 
combines scaffolding with targeted drug action. Stents coated with any of several 
pharmacotherapeutic agents such as heparin, hirudin, GP IIb/IIIa inhibitors, 
sirolimus, and paclitaxel can be used (Whan at al., 2008). The first successful 
clinical trial in 2002 led to approval of the sirolimus-eluting stents. Sirolimus 
(rapamycin) is a macrolide antibiotic with immunosuppressive and anti-mitotic 
properties effective in reducing restenosis, by inhibiting the transition of cycling cells 
from G1 to S phase (Whan et al., 2008) and it is still now one of the most common 
drugs utilized in DES. 
Although FDA approved the use of DES, there are reports of problems such 
as late stent malapposition and aneurysm formations due to the toxicity associated 
with this method of treatment and attributed to incomplete repair of the injured 
artery. Recent reports also suggest that DES may increase the risk of stent 
thrombosis relative to bare-metal stents (Yan et al., 2008) and, in addition, the long 
term effects of stents are still unknown. It is clear that the current strategies only 
allow us to buy time for individuals but it is too far to consider these the therapy to 
the restenosis. To work in this direction, the underlying molecular basis of 
restenosis are to be better clarified. 
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Figure 1.1 
Mature atherosclerotic plaque before intervention (left). Restenosis after balloon angioplasty and 
stent implantation (right) 
1.2 Mechanisms implicated in restenosis 
 The pathogenesis of restenosis is characterized by two major mechanisms: 
arterial remodelling and neointimal formation. Human and animal studies have 
shown that, in response to percutaneous coronary intervention, changes in the total 
arterial circumference occur (Post et al., 1997). It has been observed that the 
angioplasty procedure causes an actual constriction of the artery leading to the 
lumen-narrowing. On the other side, the endothelial denudation and the medial 
dissection, consequent to the intervention, induce a thrombotic response defined by 
platelet deposition and aggregation on the exposed sub-endothelial surface. 
Several growth and migratory-promoting factors, such as thrombin, platelet-derived 
growth factor (PDGF), interleukin (IL)-1, insulin-like growth factor-1 (IGF-1), 
fibroblast growth factor-2 (FGF-2), vascular endothelial cell growth factor (VEGF), 
and others are released from both injured vascular cells and platelets (Topol and 
Serruys, 1998; Lincoff et al., 1994). 
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 The complex interactions of circulating factors and multiple vascular cell 
populations promote inflammatory cell infiltration and regulate SMC 
migration/proliferation. These processes, mediated by cell surface receptors, 
culminate in transcription of early response genes necessary for cells to leave their 
quiescent state and enter the cell cycle (Sherr and Roberts, 1999). In this context 
changes in matrix synthesis, such as degradation and organization, contribute to 
both vascular remodelling and SMC activation. Indeed, after injury caused from 
arterial intervention, the upregulation of matrix metalloproteinases leads to the 
degradation of the extracellular matrix and this allows SMCs to migrate to the intima 
(Galis and Khatri, 2002). 
 Restenosis after balloon angioplasty seems to be determined primarily by the 
direction and magnitude of vessel wall remodeling. In contrast, the major limitation 
of stent implantation is the initiation of neointimal tissue proliferation within and 
adjacent to the stent (Indolfi et al., 1999). 
1.2.1 Vascular smooth muscle cell activation  
Normally, SMCs residing in the media of the vessel are in a quiescent state, 
surrounded by a basement membrane and densely packed into an interstitial 
matrix. This differentiated condition is characterized by the expression of contractile 
proteins, that are useful to keep vascular tone by contraction or relaxation, and is 
referred to contractile phenotype. However, SMCs maintain considerable plasticity 
(Owens et al., 2004): during vascular injury or disease, multiple stimuli such as 
humoral or neuronal factors, mechanical forces or cell-cell interactions, contribute to 
the disruption of the normal steady state and allow to SMCs to undergo a 
phenotypic modulation/switching (Fig. 1.2). It is characterized by dramatic increases 
in the rates of proliferation, migration, and synthesis of ECM proteins, growth 
factors and inflammatory mediators, along with decreased expression of SMC-
specific/-selective marker genes such as smooth muscle α-actin (α-SMA), smooth 
muscle-myosin heavy chain (SM-MHC), SM22α, h1-calponin, smoothelin, 
caldesmon, and telokin (Owens et al., 2004).  
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Figure 1.2 
The differentiation state of SMCs is highly plastic and dependent on integration of multiple local 
environmental cues (Figure adapted from Owens et al., 2004). 
The early markers of SMC activation, such as expression of nuclear 
oncogenes detectable immediately and/or several hours after angioplasty, is 
associated with the early G1 events preceding DNA synthesis in SMCs.  
Although the molecular mechanisms leading to SMC activation and 
phenotypic modulation are still unclear, injurious stimuli are known to alter the 
environment of the vascular wall by affecting endothelial function and inducing 
platelet adhesion and activation, migration of immune cells and changes in the 
ECM. These environmental changes subsequently induce the production of growth 
factors and cytokines by SMCs, which in turn activate autocrine/paracrine pathways 
leading to further phenotypic modulation. For example, in atherogenesis, PDGF 
produced by SMCs and other cell types, was shown to down regulate SMC 
differentiation markers such as α-SMA and SM-MHC (Owens et al., 2004); matrix 
degrading proteases produced by macrophages may contribute to the degradation 
of the basement membrane (Galis et al., 1994), and in restenosis, proteases may 
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also derive from the injured SMCs present in the lesion (Yoshida and Owens, 
2005). This activation renders the SMCs responsive to chemoattractants and 
mitogens resulting in subsequent migration and proliferation, both processes 
contributing to neointimal hyperplasia. 
1.2.2 Immune/Inflammatory response 
Although SMC activation is a prominent mechanism of the intimal hyperplasia 
at the base of the restenosis, there is strong evidence that immune/inflammatory 
response plays a critical role, too. It is known that neointimal formation is increased 
in immune-deficient animals (Dimayuga et al., 2010) indicating a significant 
correlation between injury and the immune response to injury. For several decades 
immune modulation of neointimal formation after vascular injury has been 
investigated but the complexities involved continue to obscure a clear 
understanding of this process. However, both antigen-specific and nonspecific 
immune responses could occur during restenosis. 
The major detrimental in innate immune responses associated to vascular 
injury is the macrophage infiltration. Deendothelialisation, provoked by balloon 
dilatation of the arterial wall, in fact, allows to a layer of platelets and fibrin to deposit 
at the injured site (Toutouzas et al., 2004). An interaction between platelets and 
leukocytes, that involves the platelet P-selectin and the β2 integrin molecule Mac-1 
(CD11b/CD18), promotes a process of leukocyte recruitment and infiltration, which 
is critical to the inflammatory response (Welt and Rogers, 2002). Analysis of human 
arterial segments also suggests a critical role of inflammation during in-stent 
restenosis. In the initial phase, post-stent implantation, the mural thrombus 
formation is followed by activation and invasion of SMCs, T-lymphocytes and 
macrophages. After this early neointimal formation, extracellular matrix increases; 
growth factors, cytokines and chemokines are released from leukocytes, SMCs and 
endothelial cells, thus enhancing the migration of leukocytes across the platelet-
fibrin layer into the tissue and inducing fibroblast proliferation and transformation to 
myofibroblasts (Toutouzas et al., 2004). Many chemokines such as interleukin (IL)-
8, participate in the recruitment of monocytes, leukocytes and neutrophils to areas 
of vascular injury (Welt and Rogers, 2002). Others, like monocyte chemoattractant 
protein (MCP)-1, are involved in the recruitment of monocytes, basophils and T cells 
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(Welt and Rogers, 2002), as well as activation of SMCs (Charo and Taubman, 
2004). Lately a key player in fundamental mechanisms, regulating the development 
of restenosis, as inflammation and proliferation, is the ubiquitin–proteasome system 
of intracellular protein degradation. Proteasome, in fact, is required for the activation 
of the transcription factor ―nuclear factor-κB‖ (NF-κB) by degrading its inhibitory IκB 
protein. Once activated, NF-κB induces the transcription of a large number of genes 
codifying for cytokines and chemokines involved in inflammatory and immune 
responces (Hayden and Ghosh, 2008) as well as a variety of genes related to cell 
differentiation, apoptosis, and proliferation (Karin, 2006). Cell apoptosis or necrosis, 
occurring during injury, may trigger the release of intracellular material, including 
uric acid and heat-shock proteins that can further enhance the immune activation 
(Dimayuga et al., 2010).  
All growth factors and proteases, described above, both contribute to 
neointimal formation and vessel remodeling after arterial injury (Fig. 1.3). 
 
Figure 1.3 
Immune response to arterial Injury 
The adaptive immune response appears to be more complex. Prior studies 
suggest that B lymphocytes inhibit neointimal formation (Dimayuga et al., 2005), 
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likely through the production of immunoglobulin. Similarly, experiments based on 
using T-cell depletion, T-cell deficiency, or T-cell transfer indicate the inhibitory role 
of these cells in arterial injury (Hansson et al., 1991; Remskar et al., 2001; 
Dimayuga et al., 2005). It has been observed that T lymphocytes also regulate the 
repair processes of the vasculature to injury by inhibiting SMC proliferation 
(Hansson et al., 1991). Although these data suggest a protective role of immune cell 
activation in response to arterial injury, it has been proposed that dendritic cells, 
also present in neointimal lesions, may have the capacity to induce autoimmune 
responses in T cells (Han et al., 2008) exacerbating the inflammatory response after 
vascular injury (Fig. 1.3). Because the role of T lymphocyte is still unknown, few 
studies have been conducted to investigate the effect of drug eluting stent in spite of 
the use of antiproliferative/immunesuppressive drugs. One study showed a 
significant reduction in T lymphocyte infiltration 8 months after DES implantation; 
another study showed that sirolimus DES increased CD8+ central memory T cells 
(Dimayuga et al., 2010).  
It stands to reason that the role of both innate and adaptive immunity in 
restenosis remains still unclear, thus further studies are needed to obtain a more 
comprehensive view of this growth regulatory network, also to investigate the 
benefit of current therapy, especially DES. 
 
1.3 The transcription factor nuclear factor-κB 
The inflammatory response at the base of restenosis involves several 
intracellular pathways. Among them the activation of the ubiquitous transcription 
factor NF-κB plays a critical role in the pathogenesis of the lesion.  
NF-κB is a family of transcription factors first described in 1986, now known to exist 
in virtually all cell types (Hayden and Ghosh, 2008) and organelles such as 
mitochondria (Cogswell et al., 2003). It regulates the transcription of a large number 
of genes involved in immune, inflammatory, and acute phase responses, as well as 
cell proliferation and apoptosis (Hayden and Ghosh, 2008). NF-κB family contains 5 
members: p65 (RelA), c-Rel, RelB, NF-κB1 (p50 and its precursor p105), and NF-
κB2 (p52 and its precursor p100), all of which have a structurally conserved N-
terminal ‗rel homology‘ domain responsible for dimerisation, nuclear translocation 
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and DNA binding, whereas only the first 3 contain a transactivation domain. The 
proteins can form either homodimers or heterodimers. The most widely expressed 
complex, often referred to as being ―NF-κB‖, is p65/p50 (Karin et al., 2004).  
In most cells, NF-κB is sequestered in the cytoplasm and associated with 
members of the inhibitor of NF-κB (IκB) family, which consists of IκBα, IκBβ, IκBγ, 
IκBε and Bcl-3 with IκBα being the predominant. The NF-κB-IκBα interaction inhibits 
NF-κB-DNA binding and results in the NF-κB complex being primarily in the 
cytoplasm due to a stronger nuclear export signal in IκBα, compared to the import 
signalling on NF-κB. Thus, the complex is actually continuously shuttling between 
the nucleus and the cytoplasm. In contrast, the IκBβ interaction with the NF-κB 
complex does not undergo nucleo-cytoplasmic shuttling, keeping the complex is 
retained in the cytoplasm (D‘Acquisto et al., 2002). 
NF-κB could be activated via two pathways, a canonical pathway and an 
alternative pathway (Hayden and Ghosh, 2008) (Fig. 1.4). Activation of the 
canonical NF-κB pathway is initiated by a variety of extracellular stimuli, including 
cytokines such as TNF-α and IL-1β, viral products, bacterial components such as 
LPS, and yeast products signalling through different TLRs. These agents activate 
the cells through their receptors, leading to the activation of different signalling 
cascades, which will activate the IκB kinase (IKK) complex. This complex will 
phosphorylate IκB on its N-terminal serines, resulting in its ubiquitination, 
degradation by the 26S proteasome, and translocation of the NF-κB dimer to the 
nucleus, where it binds to the NF-κB consensus sequence, leading to the 
transcription of many genes such as cytokines, adhesion molecules and 
antiapoptotic genes. The phosphorylation of IκB by the IKK complex is a convergent 
point in the activation of this classical cascade. The IKK complex comprises several 
subunits, including two highly homologous catalytic kinases, IKKα and IKKβ, and an 
essential NF-κB modulator (NEMO; IKKγ) (D‘Acquisto et al., 2002; Hayden and 
Ghosh, 2008; Cogswell et al., 2003; Karin et al., 2004). IKKβ is probably the most 
dominant kinase, whereas IKKα reveals partial redundancy for the activation of the 
classical NF-κB pathway (Li et al., 1999). NEMO is necessary for NF-κB activation 
despite lack of kinase activity (D‘Acquisto et al., 2002). IKKα was shown to be 
responsible for an alternative NF-κB activation pathway via the processing of NF-
κB2/p100 by activating lymphotoxin-β, B-cell-activating factor, CD40 ligand, and 
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LPS, some of which can induce the classical pathway (Strickland and Ghosh, 
2006).  
The relB-p52 dimers, not associated with IκB proteins, transfer to the 
nucleus, where they mediate transcription of genes involved in skin and skeletal 
development, as well as in B cell maturation (Strickland and Ghosh, 2006). IKKα 
knockout mice have many morphogenetic abnormalities, including shorter limbs and 
skull, a fused tail, and die perinatally. They exhibit a normal NF-κB activation after 
induction by IL-1β and TNF-α in embryonic fibroblasts. However, a recent study has 
revealed a new role for IKKα, which contributes to suppression of NF-κB activity 
and the resolution of inflammation in macrophages as a negative modulator. 
Inactivation of IKKα in mice enhances inflammation and bacterial clearance. 
Therefore, the two IKK catalytic subunits seem to have opposing but complimentary 
roles needed for controlling inflammation and innate immunity (Lawrence et al., 
2005). 
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Figure 1.4 
Classical and alternative NF-κB signalling pathways. The classical or canonical signalling pathway is 
represented using TNF-α as an activator. Signalling is initiated with the binding of TNF-α to its 
receptor and the subsequent sequential recruitment of the adaptors TRADD, RIP, and TRAF to the 
membrane. IKK complex assembly and recruitment to the cell membrane occurs between IKKα, 
IKKβ, and IKKγ, resulting in IKKβ phosphorylation and activation. IKKβ then phosphorylates IκBα to 
promote its polyubiquitination and subsequent immediate proteasomal degradation through β-TrCP. 
In turn, the classical p65/p50 heterodimer is freed to translocate to the nucleus and mediate 
transcription of NF-κB target genes, including one of its own inhibitor IκBα. Alternative NF-κB 
signalling is instead activated by ligands, CD40L, and lymphotoxinβ that triggers recruitment of 
TRAFs to the membrane-bound receptor and subsequently activates NIK. NIK then phosphorylates 
IKKα homodimer. Once active, IKKα phosphorylates p100, resulting in its partial proteolysis by β-
TrCP to generate the p52 subunit. The resulting RelB/p52 complex then translocates to the nucleus 
to transcribe NF-κB target genes that may be distinct from the classical pathway.(Figure adapted 
from Bakkar and Guttridge, 2010) 
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1.3.1 NF-κB in vascular injury 
NF-κB plays a critical role in the vascular response to injury (Yamasaki et al., 
2003). Activated NF-κB is detected in human atherosclerotic and restenotic lesions, 
in SMCs, monocytes, and ECs (Brand et al., 1996). In contrast, activated NF-κB is 
rarely detected in normal uninjured arteries. Activation of NF-κB is a prominent 
response of the arterial wall upon angioplasty. After vascular injury, rapid activation 
of NF-κB correlates with proliferation of SMCs and induced expression of NF-κB-
dependent genes (Brand et al., 1996). 
Findings of in vivo studies about the role of NF-κB in intimal hyperplasia 
attain the conclusion that NF-κB was involved in neointimal hyperplasia. Using a 
balloon injury model in the rat carotid artery, low levels of constitutively activated 
NF-κB were shown in normal vessels, however, immediately after injury, levels of 
ΙκBα and IκBβ (inhibitors of NF-kB) were dramatically reduced, expression of 
VCAM-1 and MCP-1 was observed (Landry et al., 1997).  
The results derived from in vitro studies consistently substantiate the notion 
that NF-κB signalling has a central role in regulating the inflammatory response and 
proliferation-apoptosis balance in the vessel wall. NF-κB regulated genes include 
TNF-α, IL-1β, IL-6, IL-10, VCAM-1, E selectin, COX-2 and iNOS. They are 
expressed in SMCs, endothelial cells and macrophages and are involved in the 
progression process (De Winther et al., 2005) even if some of them (e.g. IL-10, 
COX-2) can have anti-inflammatory roles (De Winther et al., 2005); NF-κB also 
mediates genes involved in proliferation and migration of SMCs such as MCP-1 
(Landry et al., 1997). 
These findings link the activation of NF-κB to neointimal formation and to the 
inflammatory response associated with injury-induced SMC proliferation/migration, 
thus validating NF-κB as a potential target for the control of neointimal hyperplasia.  
1.3.2 NF-κB activation as a therapeutic target in neointimal formation 
Consistent with the role of NF-κB in vascular injury, drugs specifically 
designed to target NF-κB activation, might be clinically useful for the treatment of 
diseases that involve inflammation and proliferation, including the neointimal 
hyperplasia. It is known that blocking NF-κB activation via transfection of adenoviral 
IκB (Breuss et al., 2002) or NF-κB ―decoy‖ oligodeoxynucleotides, attenuate 
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neointimal formation after balloon injury in animal models (Ohtani et al., 2006). 
Recently, the first clinical use of a NF-κB decoy at the site of coronary stenting for 
the prevention of restenosis has been described (Suzuki et al., 2009). However, the 
indispensable role played by NF-κB in many biological processes has raised 
concern that a complete shutdown of this pathway would have significant 
detrimental effects on normal cellular function. Instead, drugs that selectively target 
only the inflammation-induced NF-κB activity would be of greater therapeutic value. 
In this regard, a cell-permeable peptide, namely NEMO-binding domain (NBD) 
peptide, has been shown to inhibit the NF-κB activation during inflammatory 
responces without completely inhibit NF-κB activity (D‘Acquisto et al., 2002). It has 
not yet been investigated the possibility to consider the IKK inhibitor NBD as a 
potentially viable approach in vascular injury. The effect of this peptide on 
neointimal formation has been subject of this thesis (chapter 2). 
 
1.4 Chemokines 
Among NF-κB related proteins chemokines, a family of small heparin-binding 
proteins, play a critical role in vascular pathology. Chemokines direct the migration 
of circulating leukocytes to sites of inflammation or injury (Charo and Taubman, 
2004) and are the major stimuli for activation of SMCs after the arterial injury 
(Schober, 2008), together with growth factors and cytokines. 
It has been estimated that there may be as many as 40 to 50 human 
chemokines. Their domains are classified according to the location of cysteine 
residues (C) in highly conserved positions (Fig. 1.5). ―CXC‖ chemokines represent 
one major chemokine family and are characterized by the presence of two 
cysteines, nearest the N-termini, separated by a single amino acid. The prototypical 
member of CXC chemokines is IL-8. The other major chemokine family is called 
―CC‖ because the two cysteines are adjacent. CC chemokines are RANTES, 
macrophage inflammatory protein-1α (MIP-1α) and MIP-1β and the monocyte 
chemotactic protein (MCP) subfamily including MCP-1, MCP-2, MCP-3, MCP-4 and 
MCP-5. The third family of chemokines is denoted ―C‖ because of the lone cysteine 
in the N-terminal domain. Two chemokines have been described for this group and 
are called XCL1 (lymphotactin-α) and XCL2 (lymphotactin-ß). The last family, the 
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―CX3C‖ family, has only one known member, fractalkine (FK or CX3CL1) that 
consists of a soluble chemokine domain fused to a mucin-like stalk and a 
transmembrane domain.  
Chemokines exert their cellular effects by activating seven transmembrane– 
domain G-protein–coupled receptors. Different cell types are characterized by 
different complements of chemokine receptors; this determines whether cells 
respond to a particular chemokine set. Chemokine binding to receptor triggers an 
intracellular signal transduction cascade that activates phosphatidylinositol-3 
kinase, increases levels of inositol trisphosphate and intracellular calcium, activates 
Rho and mitogen-activated protein kinases. These events cause cell responses, 
including actin re-arrangement, shape change and chemotaxis. Chemokine 
receptors are divided into different families, CXC chemokine receptors, CC 
chemokine receptors, XC chemokine receptors and CX3C chemokine receptors that 
correspond to the four distinct families of chemokines they bind (Fig. 1.5). 
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Figure 1.5 
Classification of the four families of chemokines and their respective receptors (Figure adapted from 
Rostène et al., 2007) 
1.4.1 Chemokines as therapeutic targets in vascular pathology 
Chemokines and their receptors have a crucial role in initiating and 
progressing neointimal formation by controlling each step of the vascular 
remodelling in response to various noxious stimuli (Schober, 2008). Chemokines 
are produced by the major cells of the arterial wall, such as endothelial cells, SMCs, 
adventitial fibroblasts, leukocytes, as well as the circulation. They direct the 
leukocyte trafficking and activate the SMCs during vascular pathology (Schober, 
2008). SMCs, in fact, respond to a number of chemokines involved in cell 
proliferation or intracellular calcium mobilization resulting in induction of tissue factor 
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(Charo and Taubman, 2204), a key factor in the pathogenesis of acute coronary 
syndromes. It is well known that MCP-1 direct the monocyte homing (Schober, 
2008) as well as SMC proliferation and migration (Selzman et al., 2002; Massberg 
et al., 2003). RANTES induces the leukocyte recruitment through different 
chemokine receptors (Schober, 2008) and fractalkine  induces both inflammation 
and SMC proliferation during neointimal formation (Schober, 2008). Eotaxin 
induces migration of cultured SMCs (Kodali et al., 2004). 
The importance of chemokines in vascular diseases has sparked intense 
interest in developing broad-based inhibitors of chemokine activity as therapeutic 
agents. Several drugs, already in use as a treatment of vascular pathology or its 
risk factors, are able to modify the chemokine expression. For instance, HMG-CoA 
reductase inhibitors have been demonstrated to reduce, in vitro and in vivo, the 
expression of several markers of vascular inflammation, including chemokines 
(Apostolakis et al., 2006). Similar findings have been demonstrated for angiotensin 
converting enzyme (ACE) inhibitors, angiotensin II receptor blockade and glitazones 
(Apostolakis et al., 2006). Thus, some widely used anti-atherogenic drugs could 
mediate their beneficial actions partially through inhibition of certain chemokine 
pathways. 
Directly blocking chemokine activation is now the goal of prevention as well 
as therapy of vascular disease and several preclinical studies are ongoing in this 
sense. It has been demonstrated that intravenous infusion of the myxoma virus M-
T7, that inhibits CC and other chemokines, markedly reduced intimal hyperplasia in 
a rabbit model of arterial injury (Charo and Taubman, 2004). The chemokine 
antagonist MET-RANTES reduced neointimal formation in apolipoprotein E-
deficient (apoE-/-) mice as well as atherosclerotic plaque formation in LDLR–/– mice 
(Charo and Taubman, 2004). 
Since initiation and development of atherosclerosis and intimal hyperplasia 
after vascular injury are regulated by MCP-1 (Boring et al., 1998; Egashira et al., 
2002), MCP-1/CCR2 pathway is recently receiving increasing attention. It has been 
observed that eliminating the MCP-1 gene or blocking MCP-1 signalling decreases 
neointimal hyperplasia in several animal models of vascular injury (Furukawa et al., 
1999; Egashira et al., 2007). Catheter-based adenovirus-mediated anti-monocyte 
chemoattractant gene therapy attenuates in-stent neointimal formation in monkeys 
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(Nakano et al., 2007). Up to now the possibility to use an oral inhibitor of MCP-1 
pathway, has not yet been investigated. In this regard, an original indazolic 
compound, called bindarit, has been identified. Bindarit inhibits MCP-1 synthesis 
and its ability in reducing neointimal formation has been subject of this thesis 
(chapter 3). 
In the context of MCP-1/CCR2 pathway activation during vascular injury, it is 
interesting to note that CCR2−/− mice have a ≈60% decrease in intimal hyperplasia 
and medial DNA synthesis in response to femoral arterial injury while MCP-1−/− mice 
show a ≈30% reduction in intimal hyperplasia, which is not associated with 
diminished medial DNA synthesis (Charo and Taubman, 2004). These data suggest 
that MCP-1 and CCR2 deficiencies have distinct and separate effects on arterial 
injury; therefore, it is possible that the results obtained with CCR2−/− mice may not 
be solely mediated by MCP-1 but also by other chemokines acting on the same 
receptor. It is known that CCR2 is shared with MCP-3 and that this chemokine acts 
through interaction with not only CCR2 but also CCR1 and CCR3, all expressed on 
vascular SMCs. The role of MCP-3 in vascular pathology is not well known; in this 
thesis its effect on SMC proliferation has been evaluated (chapter 4). 
Although in the past few years we have witnessed a rapid increase in our 
understanding of the role of chemokines and their receptors in cardiovascular 
pathologies, all investigators agree on the fact that the precise mechanism of the 
chemokine pathways involved in the response of the arterial wall to vascular injury 
is not fully elucidated. Much more information is needed before chemokine-based 
therapies can be applied in clinical practice. 
 
1.5 Specific aims 
In an effort to improve on current therapy for restenosis we are prompted to 
consider new strategies for prevention and treatment. In this regard, the objective of 
the thesis was to identify molecular mechanisms and possible therapeutic targets in 
the context of immunity/inflammatory response and SMC proliferation, both 
contributing to vascular pathology in humans. Our specific aims were: 
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- to investigate the effect of two different agents, the NF-κB inhibitor NBD peptide 
and the anti-inflammatory drug bindarit, on neointimal formation in vivo, and on 
SMC proliferation/migration in vitro; 
- to evaluate the influence of MCP-3 on human coronary SMC proliferation and to 
analyse the intracellular signalling pathways involved; 
- to investigate the contribution of SMCs in antigen presentation, to better 
understand their role in vascular immunity (this part of the thesis was carried out 
in the Institute of Infection, Immunity and Inflammation, University of Glasgow, 
UK). 
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2. NBD PEPTIDE INHIBITS INJURY-INDUCED NEOINTIMAL 
FORMATION  
NF-κB plays a critical role in the pathophysiological processes leading to 
neointimal formation (Collins and Cybulsky, 2001) and it is well established that 
blocking NF-κB activation attenuates the responses to vascular injury. Activation of 
the IKK complex represents an essential regulatory step in all pathways leading to 
NF-κB activation. The ―core‖ complex containing the two catalytic subunits, IKKα 
and IKKβ, and the regulatory subunit known as NEMO or IKKγ, is an indispensable 
component of all proinflammatory signalling pathways to NF-κB. A very small region 
in the COOH-terminus of IKKα (L738–L743) and IKKβ (L737–L742) is essential for 
stable interaction with NEMO, and for the assembly of the heteromeric IKK-NEMO 
complex. This region is known as the ―NEMO binding domain‖ (NBD) (Strickland 
and Ghosh, 2006). The small size of the NBD permitted the design of a peptide that 
can disrupt the interaction of NEMO with the IKKs. To make this peptide cell 
permeable NBD peptide was conjugated to a sequence from the Drosophila 
antennapedia protein, called penetratin, that facilitates cellular uptake (May et al., 
2000) (Fig. 2.1) 
 
Figure 2.1 
The NBD region, in the COOH-terminus of IKKα and IKKβ, and the NBD peptide. AP=Penetratin 
NBD peptide, blocking the association of NEMO with IKKα and with IKKβ, 
inhibited TNF-α-induced NF-κB activation in HeLa cells, E-selectin expression in 
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human umbilical vein endothelia cells (HUVEC), NO production in macrophages 
(May et al., 2000). The potential of this peptide to function as a potent anti-
inflammatory agent has been demonstrated in vivo in various animal models 
including phorbol ester–induced ear edema and zymosan induced peritononitis 
(May et al., 2000), as well as LPS-induced septic shock (D‘Acquisto et al., 2002), 
carrageenan-induced paw swelling (D‘Acquisto et al., 2002), spontaneously 
occurring chronic murine colitis (Davé et al., 2007) and in a mouse model of 
rheumatoid arthritis, namely collagen-induced arthritis  (CIA) (Strickland and Ghosh, 
2206). However, the effects of a highly selective pharmacological inhibition of the 
proinflammatory IKK activity have not yet been investigated in vascular injury, thus 
blocking IKK through NBD peptide strategy could be interesting in this sense. 
The aim of the present study was to investigate the effect of the NBD peptide 
on neointimal formation in vivo using two well-known animal models of arterial 
injury: the rat carotid artery balloon angioplasty and the wire-induced carotid injury 
in apoE-/- mice. In addition, the effects of the NBD peptide on SMC proliferation and 
migration in vitro were also examined.  
 
2.1 Methods 
2.1.1 Cell culture 
Primary aortic SMCs were isolated from the thoracic aorta of male Wistar rats 
as previously described (Parenti et al., 2004) and grown in Dulbecco‘s modified 
Eagle medium (DMEM; Cambrex Bio Sciences) supplemented with L-glutamine, 
10% fetal bovine serum (FBS; Cambrex Bio Sciences), 100 U/mL penicillin, and 100 
µg/mL streptomycin in a humidified incubator at 37°C in 5% CO2. Before initiation of 
the assays, the SMCs were starved into DMEM supplemented with 0.1% FBS for 48 
h. Studies were performed with cells at passages 3-6. 
2.1.2 Cell proliferation study 
SMC proliferation was quantified by the total cell number as previously 
reported (Parenti, et al., 2004). Briefly, 5x103 cells were seeded onto 48-multiwell 
plates and allowed to adhere overnight. Starved cells were stimulated with TNF-α (5 
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ng/mL; R&D Systems), PDGF-BB (10 ng/mL; R&D Systems) or FGF-2 (10 ng/mL; 
R&D Systems) in the presence or absence of the NBD peptide (0.01-1 μM; 
Genosphere Biotech). After 72 h, cells were fixed with methanol and stained with 
Diff-Quik. Proliferation was evaluated as cell duplication by counting the number of 
cells in ten random fields of each well at 200X magnification (TNF-α experiment) or 
400X magnification (PDGF-BB and FGF-2 experiments) with the aid of a 21 mm2 
ocular grid. These experiments were performed in collaboration with Dr. Astrid 
Parenti, University of Florence. 
2.1.3 Chemotactic migration and invasion 
The modified Boyden chamber (48-multiwell plates; Neuroprobe) was used 
for chemotaxis studies. Polyvinyl-pyrrolidone-free polycarbonate filters, 8 µm pore 
size, were coated with 100 µg/mL collagen type I and 10 µg/mL fibronectin. Biocoat 
Matrigel invasion chambers (24-multiwell plates with 8.0 μm pore size filter; Becton 
Dickinson) were used according to the manufacturer‘s instructions for invasion 
studies. TNF-α (5 ng/mL), PDGF-BB (10 ng/mL) or FGF-2 (10 ng/mL) were added 
to the lower wells, while starved cells (12x103 for migration assay and 3x104 for 
invasion assay) were seeded into the upper wells of the chamber, and incubated at 
37°C. The NBD peptide (0.01-1 μM) was added to the cell suspension 60 min 
before seeding. After 4h for migration assay or 48h for invasion assay, the migrated 
cells were fixed and stained with haematoxylin. Cell migration was measured by 
microscopic evaluation of the number of cells moved across the filter, in ten random 
fields for the migration assay and in the entire filter for the invasion assay. Part of 
these experiments was performed in collaboration with Dr. Astrid Parenti, University 
of Florence. 
2.1.4 Flow cytometry 
Apoptosis was quantified by flow cytometry, using a commercially available 
Annexin V- Alexa Fluor® 488 apoptosis detection kit following the manufacturer‘s 
guidelines (Molecular ProbesTM). Starved SMCs were stimulated for 24h with TNF- 
(5 ng/mL) then washed twice in PBS, trypsinized, and collected. To evaluate the 
effect of the NBD peptide, SMCs were pretreated for 1h with the peptide (1 µM) 
before the TNF-α stimulation. Cells were centrifuged, the supernatant discarded, 
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and the cell pellet resuspended in the kit‘s binding buffer. The cells were centrifuged 
again, the supernatant discarded, and the pellet resuspended in the kit‘s buffer 
containing Alexa Fluor® 488 Annexin V solution and MitoTracker® Red dye. 
Samples were incubated in the dark for 10 minutes and analysed using an Epics XL 
flow cytometer (Beckman Coulter) equipped with a 488-nm Argon laser. Apoptotic 
cells showed green fluorescence with decreased red fluorescence and live cells 
showed very little green fluorescence and bright red fluorescence. Isotype-matched 
antibodies (Abs) were used as a negative control. These experiments were 
performed in collaboration with Dr. Astrid Parenti, University of Florence. 
2.1.5 Gelatin zymography 
Cells were cultured in 96-well culture plates in 10% FBS medium until 90% 
confluence was achieved. Starved cells were stimulated with TNF-Α- (5 ng/mL) in 
the presence or absence of the NBD peptide (1 μM). After 24h the media were 
collected, clarified by centrifugation and subjected to electrophoresis in 8% SDS-
PAGE containing 1 mg/mL gelatin under non-denaturing conditions. After 
electrophoresis the gels were washed with 2.5% Triton X-100 to remove SDS and 
incubated for 24 h at 37°C in 50 mM Tris buffer containing 200 mM NaCl and 20 
mM CaCl2, pH 7.4. The gels were stained with 0.5% Coomassie brilliant blue R-250 
in 10% acetic acid and 45% methanol and destained with 10% acetic acid and 45% 
methanol. Bands of gelatinase activity appeared as transparent areas against a 
blue background. Gelatinase activity was then evaluated by quantitative 
densitometry. These experiments were performed in collaboration with Dr. Astrid 
Parenti, University of Florence. 
2.1.6 Enzyme-Linked Immunosorbent Assay (ELISA) 
Cells were used after the induction of quiescence in 24-well plastic culture 
plates at a density of 2×104 cells/well. The cells were stimulated with TNF-α (5 
ng/mL) in the presence or absence of the NBD peptide (0.01-1 μM). After 24 h 
media were collected, centrifuged at 2000xg for 15 min at 4°C and supernatants 
were used for ELISA to detect MCP-1 (OptEIATM, Biosciences). 
23 
 
2.1.7 Cytosolic and nuclear extracts 
Cells (1×105) suspended in 10% FBS medium were seeded in 6-multiwell 
plates and allowed to adhere overnight. Cells were kept in starving conditions for 48 
h. The medium was then removed and replaced with fresh medium containing TNF-
α (5 ng/mL) or PDGF-BB (10 ng/mL) in the presence or absence of the NBD 
peptide (0.01-1 μM) or the mut-NBD peptide (1 μM). The NBD peptides used in this 
study were described previously (Di Meglio et al., 2005). 
The cell pellet was resuspended in 100 μL of ice-cold hypotonic lysis buffer (10 mM 
Hepes, 10 mM KCl, 0.5 mM phenylmethylsulphonyfluoride, 1.5 μg/mL soybean 
trypsin inhibitor, 7 μg/mL pepstatinA, 5 μg/mL leupeptin, 0.1 mM benzamidine, 0.5 
mM dithiothreitol) and incubated on ice for 15 min. The cells were lysed by rapid 
passage through a syringe needle five times and centrifuged for 10 min at 
13.000×g. The supernatant containing the cytosolic fraction was removed and 
stored at -80°C. The nuclear pellet was resuspended in 30 μL of high salt extraction 
buffer (20 mM Hepes pH 7.9, 10 mM NaCl, 0.2 mM EDTA, 25% v/v glycerol, 0.5 
mM phenylmethylsulphonyfluoride, 1.5 μg/mL soybean trypsin inhibitor, 7 μg/mL 
pepstatin A, 5 μg/mL leupeptin, 0.1 mM benzamidine, 0.5 mM dithiothreitol) and 
incubated at 4°C for 30 min with constant agitation. The nuclear extract was then 
centrifuged for 10 min at 6000×g with the supernatant aliquoted and stored at -
80°C. Protein concentration was determined by the Bio-Rad protein assay kit (Bio-
Rad). 
2.1.8 Western blot analysis 
Immunoblotting analysis of phospho-IκBα (Ser32/36) was performed on 
cytosolic extracts. The samples were mixed with gel loading buffer (50 mM Tris, 
10% SDS, 10% glycerol, 10% 2-mercaptoethanol, 2 mg/mL of bromophenol) in a 
ratio of 1:1, boiled for 3 min and centrifuged at 1000×g for 5 min. An equivalent 
protein amount (30 μg) of each sample was electrophoresed in a 10% 
discontinuous polyacrylamide gel. The proteins were transferred onto nitro-cellulose 
membranes, according to the manufacturer‘s instructions (Bio-Rad). The 
membranes were saturated by incubation for 2 h with 10% milk buffer and then 
incubated with the primary Ab (mouse anti-phospho-IκBα, 1:1000; Cell Signaling) at 
4°C overnight. The membranes were washed three times with 0.01% Tween20 in 
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PBS and then incubated with anti-rabbit or anti-mouse immunoglobulins coupled to 
peroxidase (1:1000; DAKO). The immunocomplexes were visualized using the ECL 
chemiluminescence method. 
2.1.9 Electrophoretic mobility shift assay (EMSA) 
Double stranded NF-κB consensus oligonucleotide probe (5‘ AGC TTC AGA 
GGG GAC TTT CCG AGA GG 3‘) was end-labelled with [32P]γ-ATP. Nuclear 
extracts (10 μg protein from each sample) were incubated for 20 min with 
radiolabelled oligonucleotides (2.5-5.0x104 cpm) in 20 μL reaction buffer containing 
2 μg poly dI-dC, 10 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM EDTA, 1 mM 
dithiothreitol, 1 μg/μL bovine serum albumin, 10% (v/v) glycerol. Nuclear protein-
oligonucleotide complexes were resolved by electrophoresis on a 5% non-
denaturing polyacrylamide gel in 0.5 x Tris-borate/EDTA at 150 V for 2 h at 4°C. 
The gels were dried and autoradiographed with intensifying screen at -80°C for 24h. 
2.1.10 Animals 
Male Wistar rats (Harlan Laboratories) weighing 250 g and 8-week-old 
female apoE-/- mice (Charles River) were used. Animals were housed at the 
Department of Experimental Pharmacology, University of Naples Federico II. All 
procedures were performed according to Italian ministerial authorization (DL 
116/92) and European regulations on the protection of animals used for 
experimental and other scientific purposes. 
2.1.11 Rat carotid balloon angioplasty 
Rats were anesthetized with an intraperitoneal injection of ketamine (100 
mg/kg) (Gellini International) and xylazine (5 mg/kg) (Sigma). Endothelial 
denudation of the left carotid artery was performed with a balloon embolectomy 
catheter (2F, Fogarty, Edwards Lifesciences) according to the procedure validated 
in our laboratories (Maffia et al., 2006). Immediately after endothelial denudation, 
300 µg of the NBD peptide or 300 μg of the mut-NBD peptide in 100 µL of pluronic 
gel (pH 7.2) was applied to the adventitia (Ianaro et al., 2003). The control group 
received pluronic gel only. Some animals were subjected to anesthesia and surgical 
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procedure without balloon injury (sham-operated group). Rats were euthanized 7 
and 14 days after angioplasty. Carotid arteries were collected and processed as 
described below. 
2.1.12 Atherogenic murine model of vascular injury 
ApoE-/- mice were fed an atherogenic diet (21% fat, 0.15% cholesterol, 
19.5% casein, wt/wt, TD88137, Mucedola) from 1 week before until 4 weeks after 
carotid injury performed as described previously (Lindner et al., 1993), with minor 
modification. Briefly, mice were anaesthetized as described above, and endothelial 
injury of the left common carotid artery was performed with a 0.35 mm diameter 
flexible nylon wire introduced through the left external carotid artery and advanced 
to the aortic arch. The endothelium was damaged by passing the wire through the 
lumen of the artery three times. Immediately after endothelial denudation, 150 g of 
the NBD peptide or 150 μg of the mut-NBD peptide in 50 µL of pluronic gel was 
applied to the adventitia. Carotid arteries were collected 28 days after wire injury 
and processed as described below. 
2.1.13 Evaluation of neointimal formation 
Carotid arteries were fixed by perfusion with phosphate-buffered saline (PBS; 
pH 7.2) followed by PBS containing 4% formaldehyde through a cannula placed in 
the left ventricle. Paraffin-embedded sections were cut (6 μm thick) from the 
approximate middle portion of the artery and stained with haematoxylin and eosin to 
demarcate cell types. Ten sections from each carotid artery were reviewed and 
scored under blind conditions. The cross-sectional areas of tunica media and 
neointima were determined by a computerized analysis system (LAS, Leica). 
2.1.14 Proliferating Cell Nuclear Antigen Analysis 
Proliferating cell nuclear antigen (PCNA) analysis was used to quantify the 
proliferative activity of cells at the balloon injury sites, and was performed using 
monoclonal mouse anti-PCNA Ab (1:250, PC10, Sigma) and biotinylated anti-
mouse secondary Ab (1:400, DakoCytomation). Slides were treated with 
streptavidin-HRP (DakoCytomation) and exposed to diaminobenzidine chromogen 
26 
 
(DakoCytomation) with hematoxylin counterstain. Six sections from each carotid 
artery and 10 fields per section were reviewed and scored under blind conditions. 
Data are represented as percentage of cells positive for PCNA 7 days after 
angioplasty. 
2.1.15 Immunohistochemical localization of the NBD peptide 
Localization of the biotinylated (bio)-NBD peptide in rat carotid arteries was 
performed by immunofluorescence in order to determine the temporal and spatial 
distribution of the peptide delivered to the adventitia. Briefly, 300 μg of the bio-NBD 
peptide (Genosphere Biotech, Paris, France) in 100 μl of pluronic gel were applied 
on the carotid artery immediately after the injury. Immunohistochemical analysis 
was performed on 5 µm frozen sections of rat carotid artery, 3, 7 and 14 days after 
injury. The biotinylated peptide was detected by texas red-conjugated streptavidin 
(1:100; DakoCytomation). For the identification of the SMCs a monoclonal anti-α-
SMA FITC (1:250, clone 1A4, Sigma) was used. DAPI was used to identify nuclei. 
2.1.16 Preparation of Total Extracts of rat carotid arteries 
All the extraction procedures were performed on ice with ice-cold reagents as 
described above. Briefly, liquid nitrogen frozen pooled carotid arteries (n=2) were 
crushed into powder and resuspended in an adequate volume of hypotonic lysis 
buffer and then centrifuged for 15 minutes at 6000xg with the supernatant being 
placed in aliquots, and stored at -80°C. Protein concentration was determined by 
the Bio-Rad protein assay kit. Total extracts were used to evaluate MCP-1 
production and NF-κB activity by ELISA and EMSA respectively.  
2.1.17 Statistical analysis 
Results are expressed as mean±SEM of n animals for in vivo experiments 
and mean±SEM of multiple experiments for in vitro assays. Student‘s t test was 
used to compare 2 groups or ANOVA (Two-Tail P value) was used with the 
Dunnett‘s post hoc test for multiple groups using Graph Pad Instat 3 software (San 
Diego). Non parametric Mann Whitney test was used for evaluation of neointimal 
formation. The level of statistical significance was 0.05 per test. 
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2.2 Results 
2.2.1 Effect of the NBD peptide on NF-κB activation in SMCs 
Thirty minutes of stimulation with TNF-α (5 ng/mL) caused a significant IκBα 
phosphorylation at Ser32 (Fig. 2.2A). Consistent with its mechanism of action, 
treatment with the NBD peptide reduced the phosphorylation of IκBα in a 
concentration-dependent manner. Treatment with the mut-NBD peptide (1 μM) did 
not affect IκBα phosphorylation (Fig. 2.2A). To further confirm the inhibitory effect of 
the NBD peptide on NF-κB activation, we examined the NF-κB/DNA binding 4h after 
TNF-α stimulation. As shown in Figure 2.2B, the NBD peptide (0.01-1 μM) inhibited 
TNF-α-induced NF-κB activation. The relative densitometric analysis showed a 
concentration-dependent inhibition, significant at all concentrations studied (Fig. 
2.2B).  
2.2.2 Effect of the NBD peptide on SMC proliferation and apoptosis 
Initiation and maintenance of SMC proliferation is a critical event in the 
pathogenesis of neointimal formation. As shown in Figure 2.3A, the NBD peptide 
(0.01-1 μM) significantly inhibited TNF-α-induced SMC proliferation by 15% 
(P<0.05, n=3), 20% (P<0.001, n=3), and 30% (P<0.001, n=3) respectively. This 
effect of the NBD peptide was not due to induction of cell apoptosis as 
demonstrated by flow cytometry analysis of Annexin V-labelled cells. The NBD 
peptide (1 µM) neither alone nor in presence of TNF-α (5 ng/mL) stimulated cell 
apoptosis (Fig. 2.3B). Similarly, the NBD peptide (1 μM) significantly inhibited 
PDGF-BB (10 ng/mL)-induced SMC proliferation by 27% (P<0.05, n=3) but was 
without effect when the stimulant was FGF-2 (10 ng/mL) (Fig. 2.4A).  
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Figure 2.2 
(A) Representative Western blot showing the effect of the NBD peptide (0.01 to 1 µM) or the mut-
NBD peptide (1µM) on rat SMC IkBα phosphorylation induced by TNF-α (5 ng/mL). (B) 
Representative EMSA and relative densitometric analysis showing the effect of the NBD peptide 
(0.01 to 1 µM) on TNF-α (5 ng/mL)-induced NF-kB activation in rat SMCs. Results are expressed as 
mean±SEM of 3 separate experiments. ***P<0.001 vs TNF-α-stimulated cells. 
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Figure 2.3 
(A) Upper panel: representative photomicrographs showing the inhibition of TNF-α-induced 
proliferation by the NBD peptide. In the lower panel the graph shows the effect of the NBD peptide 
(0.01-1 μM) on SMC proliferation induced by TNF-α (5 ng/mL). Results are expressed as 
mean±SEM of 4 experiments run in triplicate. *P<0.05; ***P<0.001 vs TNF-α-stimulated cells. (B) 
Upper panel: representative histograms of apoptotic cells (black) stimulated for 24h with TNF-α (5 
ng/mL), and the NBD peptide (1 μM) with or without TNF-α. Positive control: 1mM H2O2 for 4h. 
Isotype-matched Abs were used as negative control (white). In the lower panel the graph shows the 
effect of the NBD peptide (1 μM) with or without TNF-α on cell apoptosis. Mean  SEM of 4 
experiments. 
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Figure 2.4 
(A) Graph showing the effect of the NBD peptide (1 μM) on SMC proliferation induced by PDGF-BB 
(10 ng/mL) or FGF-2 (10 ng/mL). Results are expressed as mean ± SEM of 4 experiments run in 
triplicate. *P<0.05 vs PDGF-BB-stimulated cells without peptide. (B) Graph showing the effect of the 
NBD peptide (1 μM) on SMC migration induced by PDGFBB (10 ng/mL) or FGF-2 (10 ng/mL). 
Results are expressed as mean ± SEM of 3 experiments run in triplicate. **P<0.01 vs PDGF-BB-
stimulated cells without peptide. 
2.2.3 Effect of the NBD peptide on SMC migration 
We also evaluated the effects of the NBD peptide on TNF-α-induced SMC 
chemotaxis. The NBD peptide significantly inhibited chemotactic migration by 15% 
(P<0.05, n=3) at 0.01 μM, and about 20% (P<0.001, n=3) at both 0.1 μM and 1 μM 
(Fig. 2.5A). The NBD peptide reduced PDGF-BB-, but not FGF-2-induced SMC 
migration (Fig. 2.4B). Moreover, the NBD peptide (1 μM) significantly reduced TNF-
α-induced SMC invasion (by 70%, P<0.001, n=3) through the MatrigelTM barrier 
which mimics the extracellular matrix (Fig. 2.5B). 
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Figure 2.5 
(A) Representative photomicrographs showing the inhibition of TNF-α-induced migration by the NBD 
peptide. In the lower panel the graph shows the effect of the NBD peptide (0.01-1 μM) on SMC 
migration induced by TNF-α (5 ng/mL). Results are expressed as mean±SEM of 3 experiments run 
in triplicate. *P<0.05; ***P<0.001 vs TNF-α-stimulated cells. (B) Effect of the NBD peptide on SMC 
invasion through a matrigel
TM
 barrier induced by TNF-α. Results are expressed as mean±SEM of 3 
experiments run in triplicate. **P<0.01 vs TNF-α-stimulated cells. 
2.2.4 Effect of the NBD peptide on MMP2 and MMP9 activity 
Subconfluent cultures of SMCs were exposed to TNF-α (5 ng/mL) for 24h in 
the presence or absence of the NBD peptide (1 µM) to assess gelatinase 
production. Gelatin zymography of control supernatants showed the constitutive 
release of the latent forms of MMP-2, visualized as a band at 72 and 68 kDa. TNF-α 
stimulated the release of MMP-2 and induced its activation as revealed by the 
appearance of the 62 kDa form (Fig. 2.6A). The NBD peptide significantly (P<0.05) 
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inhibited the latent form of MMP-2 without affecting the activated form and slightly 
decreased, although not significantly, the TNF-α-induced MMP-9 gelatinase active 
form production (92 kDa) (Fig. 2.6A,B). 
 
 
Figure 2.6 
(A) Representative gel zymography of conditioned medium from SMCs and relative densitometric 
analysis showing the effect of the NBD peptide on both MMP2 latent (white columns) and activated 
(black columns) forms. Results are expressed as mean±SEM of 4 experiments. *P<0.05 vs 
unstimulated cells; °P<0.05 vs TNF-α stimulated cells. (B) Representative gel zymography of 
conditioned medium from SMCs and relative densitometric analysis showing the effect of the NBD 
peptide on MMP9 activated form. Results are expressed as mean±SEM of 4 experiments. **P<0.01 
vs unstimulated cells.  
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2.2.5 Effect of the NBD peptide on MCP-1 production 
MCP-1 production by cultured rat SMCs was determined in cell supernatants 
by ELISA. As shown in Figure 2.7, stimulation of SMCs with TNF-α (5 ng/mL) 
caused an increased release of MCP-1 compared to that observed in unstimulated 
cells. In the presence of the NBD peptide (0.01-1 μM) a concentration-related 
inhibition of MCP-1 production was observed. Interestingly, the NBD peptide, at 
higher concentrations totally abolished TNF-α-induced MCP-1 production. The NBD 
peptide alone (1 μM) did not affect basal MCP-1 production (Fig. 2.7). 
 
 
Figure 2.7 
Effect of the NBD peptide on MCP-1 production evaluated by ELISA on SMCs. Results are 
expressed as mean±SEM of 3 experiments run in triplicate. **P<0.01 and *** P<0.001 vs TNF-α-
stimulated cells. 
2.2.6 Effect of the NBD peptide on neointimal formation in rat injured carotid arteries 
Rats were treated with either the NBD peptide, the mut-NBD peptide (300 
g/site), or an equal volume of pluronic gel (100 μL, control group) immediately after 
balloon injury. A reduction of proliferating cells was demonstrated in the carotid 
arteries of the NBD peptide-treated rats 7 days after injury (P<0.01, n=5) (Fig. 
2.8A). Moreover, the NBD peptide treatment caused a significant inhibition of 
neointimal formation by 54% (P<0.01, n=10) at day 14 compared with the control 
group (Fig. 2.8B). The local application of the mut-NBD peptide (300 μg/site) did not 
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affect neointimal formation (n=5; Fig. 8B). In addition, the NBD peptide significantly 
(P<0.01) increased the lumen area and decreased neointima/media ratio (Table 
2.1). 
 
Figure 2.8 
(A) Percentage of total medial and neointimal cells positive for PCNA 7 days after vascular injury. 
Results are expressed as mean±SEM (n=5). **P<0.01 vs control group. (B) Representative 
microphotograph showing the effect of local administration of the NBD peptide (300 μg/site; n=10) or 
the mut-NBD peptide (300 μg/site; n=5) on the neointimal area in rat carotid artery, 14 days after 
injury. Control animals (n=10) received pluronic gel only as described in Methods. **P<0.01 vs 
control group. Scale bar=200 μm. 
Table 2.1 Morphometric analysis of rat carotid arteries 14 days after angioplasty 
 
 Control NBD Mut-NBD 
    
Vessel area (mm
2
) 0.457 ± 0.020 0.464 ± 0.019 0.451 ± 0.008 
Media area (mm
2
) 0.139 ± 0.018 0.132 ± 0.005 0.143 ± 0.006 
Lumen area (mm
2
) 0.108 ± 0.020 0.216 ± 0.024 ** 0.104 ± 0.027 
Neointimal area (mm
2
) 0.210 ± 0.060 0.116 ± 0.059 ** 0.202 ± 0.056 
Neointima/Media ratio  1.532 ± 0.146 0.858 ± 0.104 ** 1.410 ± 0.138 
    
The results are expressed as mean ± SEM (n=10 for control and NBD group; n=5 for mut-NBD 
group). Control animals received pluronic gel only. **P<0.01 vs control group. 
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2.2.7 Effect of the NBD peptide on NF-kB activation in rat Injured carotid arteries 
To support the hypothesis that the reduction of neointimal thickness 
correlated with NF-κB inhibition, the NF-κB/DNA binding activity was evaluated on 
extracts from carotidarteries by EMSA. The NBD peptide, but not the mut-NBD 
peptide, significantly (n=3, P<0.001) reduced balloon-induced NF-κB activation in 
injured arteries 3 and 14 days after injury. A low level of NF-κB/DNA binding activity 
was detected in total protein extracts from carotid arteries of sham-operated rats 
(Fig. 2.9A, B). 
 
Figure 2.9 
Representative EMSA and relative densitometric analysis showing the effect of the NBD peptide 
(300 μg/site; n=3) or the mut-NBD peptide (300 μg/site; n=3) on NF-κB activation in rat carotid 
arteries 3 (A) and 14 (B) days after angioplasty. Results are expressed as mean±SEM of 3 separate 
experiments. ***P<0.001 vs control group. 
36 
 
2.2.8 Effect of the NBD peptide on MCP-1 production in rat carotid arteries 
The NBD peptide was able to significantly inhibit MCP-1 protein production, 
evaluated by ELISA as described above, 7 and 14 days after injury.  (Fig. 2.10). 
 
Figure 2.10 
Effect of the NBD peptide (300 μg/site) on MCP-1 expression in rat carotid arteries 7 and 14 days 
after balloon injury evaluated by ELISA. Results are expressed as mean±SEM of MCP-1 levels 
normalized with protein concentrations, where n=3. **P<0.01 and ***P<0.001 vs control group; 
°°°P<0.001 vs sham-operated animals. Sham (grey columns), Control (black columns), NBD (white 
columns). 
2.2.9 Effect of the NBD peptide on neointimal formation in apoE-/- mice 
Carotid endothelial denudation was performed in apoE-/- mice fed an 
atherogenic diet. Twenty-eight days after injury, the neointimal area was reduced by 
46% (P<0.01) in apoE-/- mice treated with the NBD peptide compared with mut-
NBD-treated mice (Fig. 2.11). The NBD peptide significantly increased the lumen 
area (P<0.01) and decreased the neointima/media ratio (P<0.05) (Table 2.2). 
37 
 
 
Figure 2.11 
Effect of local administration of the NBD peptide (150 μg/site; n=6) on neointimal area in apoE
-/-
 
mouse carotid artery, 28 days after injury. **P<0.01 vs mut-NBD treated group (n=6). Scale bar=100 
μm. 
 
 
Table 2.2 Morphometric analysis of apoE-/- carotid arteries 28 days after injury 
 
 
NBD Mut-NBD  
   
Vessel area (μm
2
 x 10
3
) 137.25 ± 11.97 165.99 ± 8.92 
Media area (μm
2
 x 10
3
) 32.84 ± 5.66 31.58 ± 3.19 
Lumen area (μm
2
 x 10
3
) 55.25 ± 6.81 105.99 ± 9.40 ** 
Neointimal area (μm
2
 x 10
3
) 49.15 ± 2.19 28.42 ± 3.23 ** 
Neointima/Media ratio  1.88 ± 0.23 1.23 ± 0.15 * 
   
The results are expressed as mean ± SEM (n=6). **P<0.01; *P<0.05 vs mut-NBD treated group. 
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2.10 In vivo localization of the bio-NBD peptide 
No positive staining was found in non injured arteries or pluronic gel-treated 
carotids 14 days after angioplasty. In contrast, the bio-NBD peptide was detectable 
in the adventitia and media of injured vessels 3 days following injury. The bio-NBD 
peptide was also detectable in the media and the neointima at days 7 and 14 (Fig. 
2.12). 
 
 
Figure 2.12 
Immunofluorescence visualization of α-SMA (green) and bio-NBD peptide (red) in rat carotid arteries 
3, 7, and 14 days after balloon angioplasty. Dapi (blue) was used to locate nuclei. In the control 
group was used the pluronic gel only. 
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2.3 Discussion 
The results obtained in this study show that the local administration of the 
NBD peptide, a selective inhibitor of IKK activation, reduces neointimal formation in 
rodent models of vascular injury mainly by inhibiting SMC activation. Increased 
SMC proliferation and acquisition of a proinflammatory phenotype are central 
features associated with the development of neointimal lesions (Dzau et al., 2002). 
The NBD peptide showed both in vivo and in vitro antiproliferative activity. 
Treatment with the NBD peptide diminished the number of PCNA-positive 
proliferating cells in the rat vessel wall 7 days after balloon injury, concomitant with 
the beginning of neointimal formation. Furthermore, the NBD peptide inhibited in 
vitro TNF-α- and PDGF-BB-induced rat SMC proliferation and migration, effects 
associated with the inhibition of NF-κB activation. On the contrary, the NBD peptide 
showed no effect on FGF-2-induced SMC proliferation/migration. This discrepancy 
could be explained by the facts that FGF-2 induces IkB degradation and NF-κB 
activation through a pathway distinct from TNF-α (Hoshi et al., 2000) and that p38 
and p42/p44 MAPKs are also involved in FGF-2-induced SMC activation (Skaletz-
Rorowski et al., 2005). Interestingly, although the NBD peptide significantly reduced 
rat SMC invasion through the Matrigel barrier, it was able to inhibit only the latent 
form of MMP2 without significantly affecting the activated forms of both MMP2 and 
MMP9, which are known to be required for SMC proliferation and migration into the 
intimal area of vascular wall (Newby and Zaltsman, 2000; Bendeck et al., 1994). 
These results suggest that other proteases may cooperate with gelatinases in the 
TNF-α-induced cell invasion process. Activated NF-κB mediates the expression of 
several proinflammatory genes in SMCs, among which MCP-1 has been 
demonstrated to play a pivotal role in SMC proliferation/migration (Parenti et al., 
2004) and neointimal formation in several animal models (Schober and Zernecke, 
2007). Interestingly, treatment with the NBD peptide significantly inhibited MCP-1 
production, both in vitro and in vivo. Moreover, the total inhibition of MCP-1 
production and SMC proliferation observed at the highest concentration (1 µM) 
suggests that NF-κB triggers the autocrine/paracrine loop mechanism involved in 
the amplification of the inflammatory vascular response. Recent findings support the 
concept of NF-κB as a regional regulator of SMC survival rather than a direct 
promoter of proliferation of these cells (Mehrhof et al., 2005). In our experiments, 
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the highest concentration of the NBD peptide showed no effect on SMC apoptosis, 
either when used alone or when used with TNF-α. These results are in contrast with 
previous data obtained by Obara et al (Obara et al., 2000), showing increased 
apoptosis rate in TNF-α-stimulated SMCs overexpressing a truncated IkBα. Our 
results could be justified, at least in part, by the use of a selective inhibitor of the 
IKK complex formation. It is known that under physiological conditions, NF-κB is 
partially activated and involved in cell survival (Mehrhof et al., 2005). The NBD 
peptide inhibits only the inflammatory-induced NF-κB activation without modifying 
the amount constitutively activated (May et al., 2000; Baima et al., 2010). To 
confirm this point, we observed that the use of the NBD peptide, at higher 
concentrations, did not reduce the basal level of MCP-1 production compared with 
resting cells, most likely reflecting the fact that the NBD peptide does not affect 
basal NF-κB activity. In the last 10 years, NF-κB has been investigated as a novel 
therapeutic target to prevent restenosis. However, the potential for developing 
effective therapeutic strategies based on NF-κB blockade remains to be 
determined. Several studies have targeted NF-κB activation in the control of 
vascular injury (Ohtani et al., 2006) and a phase I/IIa open-label multicenter study to 
assess the inhibitory effects of an NF-κB ODN decoy on in-stent coronary 
restenosis (INDOR Study) has reported the clinical safety of such approach in 
humans (Egashira et al., 2008). In contrast to other therapeutic principles, the 
inhibition of the NF-κB system represents a broad-spectrum, multipurpose weapon 
that can interfere with several fundamntal pathophysiological mechanisms in the 
development of neointimal formation, targeting both proliferation and inflammation. 
In our study, the use of a peptide that selectively inhibits the IKK complex 
represents a novel and interesting approach. Compared with other NF-κB inhibitors 
tested to inhibit neointimal formation, the NBD peptide has the advantage of 
inhibiting the induction of NF-κB activation without inhibiting basal NF-κB activity 
that may be involved in fundamental cellular processes (May et al., 2000; Baima et 
al., 2010). Notably, the continuous administration of the peptide for >45 days did not 
lead to overt toxicity in mice (Jimi et al., 2004 ). Importantly, the Pluronic F-127 gel 
has been shown to be absorbed in vivo at 3 days. Such a short-term local 
administration of traditional NF-κB inhibitors (eg, pyrrolidine dithiocarbamate) has 
been shown to inhibit NF-κB activation in the injured vessels at day 3, without 
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affecting intimal formation at day 14. (Bu et al., 2005) Intriguingly, using the same 
delivery approach, we have clearly shown the presence of the biotinylated peptide 
in the rat media and neointima up to 14 days after injury. Importantly, the NBD 
peptide efficacy was also confirmed in the hyperlipidemic mouse model, 
demonstrating the efficacy of the peptide under circumstances of increased 
vascular inflammation (Maffia et al. 2007). Neither rodent model is a reliable 
experimental model of human angioplasty, and as such, the present study has 
some limitations. It would be desirable to explore the efficacy and therapeutic 
potential of the NBD peptide in larger preclinical animal models. However, our 
results demonstrate the involvement of NF-κB as a regulator in the formation of 
neointima in mouse and rat vascular injury models and support the use of specific 
IKK inhibitors to reduce neointimal hyperplasia. 
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3. THE ANTI-INFLAMMATORY AGENT BINDARIT INHIBITS 
NEOINTIMAL FORMATION IN BOTH RATS AND HYPERLIPIDAEMIC 
MICE 
Bindarit is an original indazolic derivative able to inhibit MCP-1/CCL2, MCP-
2/CCL8 and MCP-3/CCL7 synthesis (Mirolo et al., 2008) (Fig. 3.1). Although it 
shows neither immunosuppressive effects nor activity on arachidonic acid 
metabolism, it has a potent anti-inflammatory activity in a number of experimental 
models including nephritis, arthritis, pancreatitis and colitis (Zoja et al., 1998; 
Guglielmotti et al., 2002; Bhatia et al., 2005; Bhatia et al., 2008) as well as in 
reducing myocardial and renal dysfunction in swine renovascular hypertension (Lin 
et al., 2009; Zhu et al., 2009). Phase II clinical trials have shown that bindarit is well 
tolerated and significantly reduced urinary MCP-1 and albumin excretion in kidney 
disease (Perico et al.,2008; Guglielmotti et al.,2009). 
 
 
 
Figure 3.1  
2-Methyl-2-[[1-(phenylmethyl)-1H-indazol-3yl]methoxy]propanoic acid (bindarit) 
As described above, chemokines have been implicated in the response of the 
arterial wall to injury. Among pro-inflammatory CC chemokines, MCP-1 is one of the 
most interesting in this sence. Elevated circulating levels of MCP-1 were observed 
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in patients with restenosis after coronary angioplasty (Cipollone et al., 2001). 
Moreover blocking MCP-1 pathway decreases neointimal hyperplasia in preclinical 
models of vascular injury (Furukawa et al., 1999; Egashira et al.,2007; Nakano et 
al.,2007). These data suggest that an anti-inflammatory treatment based on the 
inhibition of MCP-1 may be an appropriate and reasonable approach for the 
prevention of neointimal formation. 
Here, we investigated the effect of bindarit on neointimal formation in vivo 
using the carotid artery balloon angioplasty model in rats and the wire-induced 
carotid injury model in apoE−/− mice. In addition, the effects of bindarit on SMC 
proliferation and migration in vitro were also examined.  
 
3.1 Methods 
3.1.1 Treatments 
Bindarit, 2-methyl-2-[[1-(phenylmethyl)-1H-indazol-3-yl]methoxy] propanoic 
acid (MW 324.38), was synthesized by Angelini (Angelini Research Center—
ACRAF, Italy). Pharmacokinetic studies in rodents show that bindarit is well 
absorbed when administered by oral route, and it has a mean half-life of ∼9 h and, 
at dose regimen used in this study, reaches plasma levels in the range of 150–450 
µM (Product data sheet, Angelini Research Center). Animals were treated with 
bindarit, suspended in 0.5% methylcellulose aqueous solution, at the dose of 100 
mg/kg given orally, by gastric gavage, twice a day (Bhatia et al., 2008). Rats were 
treated with bindarit from 2 days before angioplasty up to 14 days after, whereas 
apoE−/− mice were treated from 1 week before endothelial denudation up to 28 days 
after. In each experiment, control animals received an equal volume of 
methylcellulose (0.5 mL/100 g in rats; 0.1 mL/10 g in mice). The concentrations of 
bindarit used for in vitro experiments have been found previously to be effective at 
inhibiting MCP-1 synthesis in human monocytes and umbilical vein endothelial cells 
(Mirolo et al., 2008). 
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3.1.2 Cell culture 
Primary aortic SMCs isolated from aorta of rats or apoE−/− mice were used as  
described above (chapter 2, section 2.1.1) 
3.1.3 Enzyme-linked immunosorbent assay (ELISA) for MCP-1 protein 
Cells were used after the induction of quiescence in 24-well plastic culture 
plates at a density of 1.5 × 104 cells/well. The cells were stimulated with platelet 
derived growth factor-BB (PDGF-BB; 10 ng/mL; R&D Systems) in the presence or 
absence of bindarit (10–300 µM). After 6, 12, 24, and 48 h, media were collected, 
centrifuged at 2000 g for 15 min at 4°C, and supernatants were used for enzyme-
linked immunosorbent assay (ELISA) (OptEIA™, Biosciences). 
3.1.4 Proliferation assay 
The cell proliferation assay was carried out using the MTT assay. SMCs were 
plated on 24-well plastic culture plates at the density of 1.5 × 104 cells/well and 
then incubated with DMEM containing PDGF-BB (10 ng/mL) for 48 h in the 
presence or absence of bindarit (10–300 µM). The absorbance values were 
obtained with an ELISA assay reader (630 nm). 
3.1.5 Chemotactic migration and invasion 
SMC migration was evaluated using a modified Boyden chamber (Corning 24 
mm Transwell with 8.0 µm pore polycarbonate membrane insert) coated with rat-
tail collagen I (Sigma-Aldrich). Biocoat Matrigel invasion chambers (with 8.0 µm 
pore) were used according to the manufacturer's instructions for invasion studies 
(Becton–Dickinson). Briefly, starved SMCs were trypsinized and pre-treated or not 
with bindarit (10–300 µM) for 2 h. 5 × 105 cells were plated in the upper chamber 
in 150 µL of 1% FBS medium with or without bindarit (10–300 µM) and the lower 
chamber was filled with 600 µL of 1% FBS medium in the absence (untreated 
cells) or presence of PDGF-BB 10 ng/mL. After 6 h for migration assay or 48 h for 
invasion assay, the migrated cells were fixed and stained with haematoxylin. The 
number of migrated cells was counted in eight randomly chosen fields per insert. 
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3.1.6 Animals 
The investigation conforms to the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH Publication No. 85-
23, revised 1996), and Italian ministerial authorization (DL 116/92) was obtained to 
carry out the experimentation. Male Wistar rats (Harlan Laboratories) weighing 250 
g and 8-week-old female apoE−/− mice (Charles River) were used for the present 
study. Animals were housed at the Department of Experimental Pharmacology, 
University of Naples Federico II. 
3.1.7 Rat carotid balloon angioplasty 
Balloon-induced carotid injury in rats was performed as described above 
(chapter 2, section 2.1.11). Blood and carotid arteries were collected and processed 
as described below. 
3.1.8 Atherogenic murine model of vascular injury 
Wire-induced carotid injury in apoE
−/− 
mice was performed as described 
above (chapter 2, section 2.1.12). Blood and carotid arteries were collected 7 and 
28 days after wire injury and processed as described below. 
3.1.9 Evaluation of neointimal formation 
Carotid arteries from rats or apoE−/− mice were fixed by perfusion with 
phosphate-buffered saline (PBS; pH 7.2) followed by PBS containing 4% 
formaldehyde through a cannula placed in the left ventricle. Paraffin-embedded 
sections were cut (6 µm thick) from the approximate middle portion of the artery and 
stained with haematoxylin and eosin to demarcate cell types. Ten sections from 
each carotid artery were reviewed and scored under blind conditions. The cross-
sectional areas of media and neointima were determined by a computerized 
analysis system (LAS, Leica). 
3.1.10 Proliferating cell nuclear antigen analysis in injured rat carotid arteries 
Proliferating cell nuclear antigen (PCNA) analysis was used to quantify the 
proliferative activity of cells at the injury sites and was performed using monoclonal 
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mouse anti-PCNA Ab (1:250, PC10, Sigma) and biotinylated anti-mouse secondary 
Ab (1:400, DakoCytomation). Slides were treated with streptavidin–HRP 
(DakoCytomation) and exposed to diaminobenzidine chromogen (DakoCytomation) 
with haematoxylin counterstain. The proliferating cell number in the rat carotid 
arteries was scored in 10 fields for each section, six sections from each carotid 
artery, and expressed as the percentage of total medial and neointimal cells positive 
for PCNA 7 days after angioplasty. The proliferating cell number in the mouse 
apoE−/− carotid arteries was scored in 10 sections from each carotid artery and 
expressed as the percentage of positive cells 7 days after wire injury. 
3.1.11 MCP-1 immunohistochemistry 
Rat carotid arteries (1, 7, and 14 days after angioplasty, or naive) were snap-
frozen in liquid nitrogen in OCT embedding medium (Tissue Tek, Sakura Finetek). 
Ten cross-sections were cut (6 µm) from the approximate middle portion of the 
artery and used for MCP-1 detection. Sections were incubated with polyclonal goat 
anti-MCP-1 Ab (1:50, R-17, Santa Cruz) diluted in blocking buffer/0.3% Triton X-100 
(MP Biomedicals) in PBS overnight before being washed in TNT wash buffer (Tris–
HCl, pH 7.5, 0.15 M NaCl, and 0.05% Tween 20; Sigma). Sections incubated with 
goat non-immune serum were used as negative controls. Subsequently, sections 
were incubated with biotinylated anti-goat secondary Ab (1:400, DakoCytomation) 
diluted in blocking buffer/0.3% Triton X-100, washed in TNT wash buffer, treated 
with streptavidin–HRP, and exposed to diaminobenzidine chromogen with 
haematoxylin counterstain. The sections were photographed and the images were 
stored in the image analysis system (LAS, Leica). 
3.1.12 Enzyme-linked immunosorbent assay (ELISA) 
Rat carotid arteries were crushed into powder and resuspended in 100 µL of 
lysis buffer (20 mM HEPES, 0.4 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 1 mM 
EDTA, 1% Triton X-100, and 20% glycerol) with protease inhibitors (1 mM DTT, 0.5 
mM PMSF, 15 µg/mL Try-inhibitor, 3 µg/mL pepstatin-A, 2 µg/mL leupeptin, and 40 
µM benzamidine). After centrifugation at 13 000 g at 4°C for 30 min, MCP-1 in the 
supernatant was quantified using an ELISA kit (OptEIA™, Biosciences). All 
measurements were performed in duplicate. The values were corrected by protein 
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concentrations measured by the Bio-Rad protein assay kit (Bio-Rad). Serum MCP-1 
levels (1, 7, and 14 days after angioplasty) were also measured in the same 
animals used above by ELISA (OptEIA™, Biosciences). The results are expressed 
as nanograms per millilitre. 
3.1.13 Western blot analysis 
The levels of CD68 were evaluated in total extracts prepared from two pooled 
rat carotid arteries. The extraction procedure was performed as described above. 
Protein concentration was determined by the Bio-Rad protein assay kit (Bio-Rad). 
Equivalent amounts of protein (50 µg) from each sample were electrophoresed in 
an 8% discontinuous polyacrylamide minigel. The proteins were transferred onto 
nitrocellulose membranes according to the manufacturer's instructions (Bio-Rad). 
The membranes were saturated by incubation with 10% non-fat dry milk in 
PBS/0.1% Triton X-100 for 3 h at room temperature and then incubated with anti-
CD68 mouse Ab (1:1000; Serotec) or anti-β-actin (1:5000; Sigma) mouse Ab 
overnight at 4°C. The membranes were washed three times with 0.1% Tween 20 in 
PBS and then incubated with anti-mouse immunoglobulins coupled to peroxidase 
(1:1000; DakoCytomation) for 1 h at room temperature. The immune complexes 
were visualized by enhanced chemiluminescence (Amersham). Subsequently, the 
relative intensities of the bands were quantified by densitometric scanning of the X-
ray films with a GS-800 Imaging Densitometer (Bio-Rad) and the computer program 
‗Quantity One‘ (Bio-Rad). Results are expressed as arbitrary units of CD68 protein 
levels, normalized to protein levels of the housekeeping protein β-actin. 
3.1.14 Evaluation of re-endothelialisation in injured rat carotid arteries 
Re-endothelialisation was assessed 2 weeks after balloon injury by staining 
with Evans Blue dye (0.5 mL of 0.5% Evans Blue dye iv; Sigma) as described 
previously (Asahara et al., 1996). Planimetric analysis with an image analysis 
program (LAS, Leica) was performed. Re-endothelialisation was expressed as the 
percentage of re-endothelialised area vs the total denuded area. To verify that the 
Evans Blue stain accurately depicted the presence or absence of endothelium, 
sections of completely or partially re-endothelialised carotid arteries (based on 
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Evans Blue appearance) were stained with Ab to von Willebrand factor (vWF, 
Cytomation Dako) as described previously (Yue et al., 2000). 
3.1.15 Immunohistochemisty analysis in injured apoE-/- mouse carotid arteries 
Carotid arteries were snap-frozen in liquid nitrogen in OCT embedding 
medium. Fifteen cross-sections were cut (6 µm) from the approximate middle 
portion of the artery and used for MCP-1, α-smooth muscle actin (α-SMA), and 
macrophage detection by immunofluorescence. For staining, the sections were 
processed as described above and incubated with polyclonal goat anti-mouse MCP-
1 Ab (1:50, M-18, Santa Cruz) or rat anti-F4/80 monoclonal Ab (1:50, clone BM8, 
Abcam) diluted in blocking buffer/0.3% Triton X-100 (MP Biomedicals) in PBS 
overnight before being washed in TNT wash buffer. Sections incubated with non-
immune goat serum or an isotype-matched control Ab were used as negative 
controls. Subsequently, the sections were incubated with 1:75 Texas Red-donkey 
anti-goat IgG (Jackson ImmunoResearch Laboratories) or with 1:200 biotinylated 
anti-rat secondary Ab (DakoCytomation), amplified with Tyramide Signal 
Amplification Systems (PerkinElmer), and revealed with streptavidin–FITC (1:50, 
DakoCytomation). Monoclonal anti-α-SMA FITC (1:250, clone 1A4, Sigma) was 
added in blocking buffer for 1 h before washing as described above. DAPI was used 
to identify nuclei. Images were taken using an AxioCam HRc video-camera (Zeiss) 
connected to an Axioplan fluorescence microscope (Zeiss) using the AxioVision 3.1 
software. The neointimal areas stained for F4/80 were determined in digitized 
images (five sections per mouse), and positive areas for specific immunostaining 
were quantified (NIH Imaging; http://rsb.info.nih.gov/ij). Data are expressed as the 
percentage of the immunostained area per total neointimal area. 
Serial carotid paraffin-embedded sections were cut (5 µm) and used for detection of 
calponin (1:100, clone hCP, Sigma). Ten sections from each carotid artery were 
reviewed and scored under blind conditions. The number of calponin-positive cells 
in neointima was counted. 
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3.1.16 Evaluation of MCP-1, total cholesterol, and triglyceride serum levels in  
apoE-/- mice 
The concentrations of serum MCP-1, triglycerides, and cholesterol were 
determined using enzymatic immunoassays according to the manufacturer's 
instructions (OptEIA™, Biosciences; Serum Triglyceride Kit, Sigma; Cholesterol 
Assay Kit, Cayman Chemical). 
3.1.17 Statistical analysis 
Results are expressed as mean±SEM of n animals for in vivo experiments 
and mean±SEM of multiple experiments for in vitro assays. Student's t-test was 
used to compare two groups and ANOVA (two-tailed P-value) was used with the 
Dunnett post hoc test for multiple groups using Graph Pad Instat 3 software (San 
Diego). The level of statistical significance was 0.05 per test. 
 
3.2 Results 
3.2.1 Effect of bindarit on rat SMC proliferation and migration 
As shown in Figure 3.2A, bindarit at 100 and 300 µM significantly inhibited 
PDGF-BB-induced rat SMC proliferation by 27% (P<0.05, n=3) and 42% 
(P<0.01, n=3), respectively. Another key mechanism of neointimal formation is 
mitogen-mediated migration of SMCs. Therefore, we evaluated the effects of 
bindarit on PDGF-BB-induced rat SMC chemotaxis. Bindarit inhibited significantly 
(P<0.01, n=3) chemotactic migration at 100 and 300 µM by 45 and 50%, 
respectively (Fig. 3.2B). Moreover, bindarit (100 µM) also significantly reduced rat 
SMC invasion (by 30%, P<0.01, n=3, Fig. 3.2C) through the Matrigel barrier which 
mimics extracellular matrix.  
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Figure 3.2  
(A) Effect of bindarit (10–300 µM) on rat SMC proliferation, (B) migration, and (C) invasion performed 
as described in Section 2. Results are expressed as mean±SEM from three separate experiments. 
*P<0.05, **P<0.01 vs platelet derived growth factor-BB (PDGF-BB); °°P<0.01, °°°P<0.001 vs 
unstimulated cells. 
3.2.2 Effect of bindarit on MCP-1 production 
To determine whether the anti-proliferative and anti-migratory effects of 
bindarit were associated with MCP-1 inhibition, protein concentration of MCP-1 in 
the supernatant of cultured rat SMCs was determined by ELISA. As shown in Table 
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3.1, stimulation of SMCs with PDGF-BB (10 ng/mL) caused a time-dependent 
increased release of MCP-1 compared with that observed in unstimulated cells. 
When rat SMCs were stimulated with PDGF-BB in the presence of bindarit (10–300 
µM), a concentration-related inhibition of MCP-1 production was observed. 
 
 
Table 3.1 Effect of bindarit on MCP-1 production by PDGF-BB-stimulated SMCs 
 
 MCP-1 (ng/mL) 
6h 12h 24h 48h 
     
Unstimulated cells 0.320.02  3.20.21    18.50.9   34.11.4 
PDGF-BB 10 ng/mL 3.10.1°° 20.81.58°° 59.60.4°° 142.62.8°° 
PDGF-BB 10 ng/mL + bindarit 10 M 3.00.2   18.31.2 50.91.2** 128.03.7** 
PDGF-BB 10 ng/mL + bindarit 30 M 1.50.1** 13.70.5** 42.80.6** 87.31.7** 
PDGF-BB 10 ng/mL + bindarit 100 M 1.30.2** 11.90.4** 34.01.0** 80.11.8** 
PDGF-BB 10 ng/mL + bindarit 300 M 0.80.1** 4.80.5** 29.31.1** 72.11.3** 
Results are expressed as meanSEM of three separate experiments run in triplicate. 
°° P<0.01 vs unstimulated cells; ** P<0.01 vs PDGF-BB 
 
 
3.2.3 Effect of bindarit on neointimal formation in rat carotid arteries 
To determine the efficacy of a systemic treatment with bindarit for the 
limitation of neointimal hyperplasia, a rat carotid arterial injury model was used. A 
remarkable increase in the number of PCNA-positive cells was demonstrated in 
both the media and neointima 7 days after injury in control rats, which was 
significantly reduced (P<0.001, n=9) in the bindarit-treated group (200 mg/kg/day) 
by 54 and 30%, respectively (Fig. 3.3A). Bindarit caused a significant inhibition of 
neointimal formation by 39% (P<0.01, n=19) at day 14 compared with the control 
animals (Fig. 3.3B). Medial area (0.124±0.003 mm2 in the sham group) was not 
affected by both vascular injury and bindarit. 
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Figure 3.3 
(A) Photomicrographs showing the effect of bindarit (200 mg/kg/day) on PCNA-positive cells in rat 
carotid arteries at day 7 after injury (magnification x 400). Results are expressed as mean+SEM of 
the percentage of total medial and neointimal cells positive for PCNA as described in Section 2, 
where n=9 rats for each group. ***P<0.001 vs control group. (B) Photomicrographs showing the 
effect of bindarit (200 mg/kg/day) on neointimal formation in rat carotid arteries 14 days after balloon 
injury (magnification x 100). Results are expressed as mean+SEM, where n=15–19 rats. **P<0.01 vs 
control group. 
3.2.4 Effect of bindarit on monocytes/macrophages infiltration in rat carotid arteries 
Western blot analysis was performed to examine the effect of bindarit on the 
carotid monocyte/macrophage content. Monocyte/macrophage marker CD68 was 
highly expressed in carotid arteries 14 days after angioplasty when compared with 
that of sham-operated animals (Fig. 3.4). Bindarit significantly reduced CD68 levels 
as shown by relative densitometric analysis. 
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Figure 3.4 
Effect of bindarit (200 mg/kg/day) on monocyte/macrophage marker CD68 protein expression in 
carotid arteries 14 days after angioplasty. Equal loading was confirmed by b-acting staining. Results 
are expressed as mean+SEM of three separate experiments. **P<0.01 vs control group. 
3.2.5 Effect of bindarit on MCP-1 production in rat carotid arteries 
We observed a significant time-dependent increase in MCP-1 production in 
the injured arteries at 1, 7, and 14 days after angioplasty when compared with that 
of sham-operated animals (Fig. 3.5). Bindarit was able to inhibit the MCP-1 protein 
expression throughout the time course considered, by 31% (P<0.05; n=5), 38% 
(P<0.05; n=5), and 49% (P<0.001; n=5) at 1, 7, and 14 days after injury, 
respectively. In carotid arteries from naive animals, the levels of MCP-1 measured 
were 0.74±0.34 ng/mg (n=5). 
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Figure 3.5 
Effect of bindarit (200 mg/kg/day) on MCP-1 expression in rat carotid arteries 1, 7, and 14 days after 
balloon injury evaluated by ELISA. Results are expressed as mean+SEM of MCP-1 levels 
normalized with protein concentrations, where n=5. *P<0.05; ***P<0.001 vs control group; 
°°°P<0.001 vs sham-operated animals. 
3.2.6 Effect of bindarit on MCP-1 localization in rat carotid arteries 
Non-injured carotid arteries lacked immunoreactivity for MCP-1, whereas 
injured arteries stained strongly for MCP-1 (Fig. 3.6). Negative controls showed no 
signal. MCP-1-positive staining was detectable in media of injured vessel from days 
1 up to 14 and in neointimal cells at days 7 and 14. MCP-1 localization was not 
modified by bindarit, whereas the drug treatment resulted in a lower MCP-1 
expression in both media and neointima (Fig. 3.6). 
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Figure 3.6  
Immohistochemical localization of MCP-1 expression in rat carotid arteries 1, 7, and 14 days after 
angioplasty. 
3.2.7 Effect of bindarit on re-endothelialisation in rat carotid arteries 
Evans Blue staining identifies segments of injured carotid arteries that have 
not been re-endothelialised. As shown in Figure 3.7, the presence of intact 
endothelium in the carotid artery of naive rats was demonstrated by the absence of 
Evans Blue staining. Immunohistochemical staining with Ab to vWF verified the 
presence of endothelium. In contrast, the entire area of the artery harvested 1 day 
after injury was stained by Evans Blue. The absence of positive staining with Ab to 
vWF confirmed the observation. Analysis of samples at 2 weeks from angioplasty 
showed that bindarit treatment did not affect re-endothelialisation of arteries when 
compared with control animals. 
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Figure 3.7  
Extent of re-endothelialisation in injured carotid arteries evaluated by Evans Blue staining. 
Representative arteries harvested from naïve animals, as well as 1 and 14 days after carotid injury in 
vehicle- or bindarit treated rats. Evans Blue staining identifies segments of each artery that have not 
been recovered by endothelium. Immunohistochemical staining with Ab to vWF verified the presence 
of endothelium. Re-endothelialisation was expressed as the percentage of re-endothelialised area vs 
the total denuded area (bottom panel) (n=5). 
3.2.8 Effect of bindarit on MCP-1 serum levels 
A time-dependent increase in MCP-1 serum concentration was observed in 
rats subjected to angioplasty (Table 3.2). Bindarit caused a significant inhibition of 
MCP-1 serum levels at day 1 by 20% (P<0.05, n=10) and at days 7 and 14 by 30% 
(P<0.001, n=10) compared with their respective control groups. In naive animals, 
the MCP-1 serum level was 29.4±3.0 ng/mL (n=5). 
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Table 3.2 Effect of bindarit on MCP-1 serum levels in rats 
 MCP-1 (ng/mL) 
Group 1-day 7-day 14-day 
    
sham-operated 
 
37.1±2.4 35.4±1.2    32.8±2.7 
Control 
 
69.2±3.5°° 51.4±2.2°° 53.7±3.9°° 
bindarit (200 mg/kg/day) 
 
55.6±3.0* 36.2±2.4*** 37.2±2.1*** 
Results are expressed as meanSEM where n=5-10 rats per each time point considered. 
°°P<0.01 vs sham-operated animals; * P<0.05; *** P<0.001 vs control group. 
 
 
3.2.9 Effect of bindarit on neointimal formation in apoE-/- mice 
To evaluate the effect of bindarit after arterial injury in hyperlipidaemic 
animals, carotid endothelial denudation was performed in apoE−/− mice fed an 
atherogenic diet. Seven days after injury, the number of PCNA-positive cells was 
significantly reduced (42%; P<0.05, n=10) by treatment with bindarit (200 
mg/kg/day) compared with control mice (Fig. 3.8A). Neointimal area was reduced by 
47% in apoE−/− mice treated with bindarit compared with control mice 28 days after 
injury (Fig. 3.8B). Moreover, the apoE−/−mice receiving bindarit showed a 66% 
reduction in the relative content of F4/80-positive macrophages and a 30% 
reduction in the number of SMCs in neointimal lesion (Fig. 3.8 C and D). 
Injured carotid arteries stained strongly for MCP-1 detectable in media and 
neointima 28 days after injury. Co-localization of MCP-1 and α-actin was evident in 
both media and neointima. MCP-1 localization was not modified by bindarit, but 
again the drug reduced both medial and neointimal MCP-1 expression (Fig. 3.9). 
Total cholesterol levels did not differ between groups (1036±38 mg/dL in bindarit-
treated group, n=10 vs 1167±50 mg/dL in control group, n=10), whereas triglyceride 
levels were significantly lower (P<0.05) in bindarit-treated animals (191.6±21.3 
mg/dL, n=10) than in the control group (260.7±20.6 mg/dL, n=10). Moreover, 
bindarit caused a significant inhibition (P<0.01) of MCP-1 serum levels by 42% 
(131.0±15.6 pg/mL in bindarit-treated group, n=10 vs 224.8±28.3 pg/mL in control 
group, n=10; P<0.01). 
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Figure 3.8  
(A) Photomicrographs showing the effect of bindarit (200 mg/kg/day) on PCNA-positive cells in  
apoE
-/-
 mice 7 days after injury (magnification x400). Results are expressed as mean+SEM of the 
percentage of total PCNA-positive cells as described in Section 2, where n=10 rats for each group. 
*P<0.05 vs control group. (B) Photomicrographs showing the effect of bindarit (200 mg/kg/day) on 
neointimal formation in apoE
-/-
 mice 28 days after carotid injury (magnification x100). Results are 
expressed as mean+SEM, where n=10 for each group; **P<0.01 vs control group. (C) 
Photomicrographs showing the effect of bindarit (200 mg/kg/day) on macrophage content in carotid 
arteries 28 days after injury (magnification x400). Results are expressed as mean+SEM of the 
percentage of F4/80 immunostained area per total neointimal area, where n=10 for each group; 
***P<0.001 vs control group. (D) Photomicrographs showing the effect of bindarit (200 mg/kg/day) on 
neointimal SMC content in carotid arteries 28 days after injury (magnification x 100). Results are 
expressed as mean+SEM of the calponin-immunostained cell number, where n=10 for each group; 
*P<0.05 vs control group.  
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Figure 3.9 
Immunofluorescence visualization of α-SMA (green) and MCP-1 (red) in mouse carotid arteries 28 
days after injury. DAPI (blue) was used to locate nuclei. Co-localization of MCP-1 and α-actin 
(yellow) was evident in some cells in both media and neointima (magnification x 200). 
3.3 Discussion 
The results provided in this study show that bindarit given systemically 
signiﬁcantly reduced neointimal formation in animal models of arterial injury by 
inhibiting SMC proliferation/migration, and macrophage inﬁltration; these effects 
correlated with a reduction in MCP-1 synthesis. Bindarit is an original compound 
selected by screening a series of indazolic derivatives endowed with peculiar 
antiinﬂammatory activity associated with a selective inhibition of a subfamily of CC 
inﬂammatory chemokines, including MCP-1/CCL2, MCP-3/CCL7, and MCP-
2/CCL8, showing no effect on other CC and CXC chemokines such as MIP-
1a/CCL3, MIP-1b/CCL4, MIP-3/CCL23, RANTES/CCL5, and IL8/CXCL8 (Zoja et 
al., 1998; Guglielmotti et al., 2002; Bhatia et al., 2005; Bhatia et al., 2008; Mirolo et 
al., 2008). After vascular damage, the rat carotid artery develops neointimal 
formation, mainly due to proliferation and migration of SMCs, that causes a clear 
narrowing of the vessel lumen. Neointimal formation contributes to the development 
of restenosis after coronary artery angioplasty, with or without stenting, in which a 
pivotal mechanism is represented by the loss of differentiation of SMCs that were 
able to proliferate and migrate (Owens et al., 2004). It is well known that among pro-
inﬂammatory CC chemokines, MCP-1 is implicated in all these processes and the 
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source of this chemokine is likely to include the major cells in injured arteries, such 
as endothelial cells, SMCs, and macrophages (Charo and Taubman, 2004). In 
injured carotid arteries from animals treated with bindarit, a signiﬁcant inhibition of 
neointimal formation associated with a reduced MCP-1 production was observed. 
Bindarit did not modify MCP-1 localization but reduced MCP-1 expression in both 
media and neointima. Moreover, bindarit caused a signiﬁcant inhibition of MCP-1 
serum levels. Increased levels of circulating MCP-1 in animals subjected to vascular 
injury are in keeping with an active role for this chemokine in tissue pathogenesis 
and correlate with epidemiological evidence showing higher MCP-1 plasma levels 
associated with human restenosis (Cipollone et al., 2001; Martinovic et al., 2005). 
Bindarit showed both in vivo and in vitro antiproliferative effects. For example, 
bindarit diminished the number of PCNA-positive proliferating cells in the media and 
intima 7 days after angioplasty, concomitantly with the beginning of neointimal 
formation, without affecting re-endothelialisation evaluated 14 days after injury. In 
vitro studies further demonstrated inhibitory effects of bindarit on PDGF-BB-
stimulated rat SMC proliferation and migration. These effects were associated with 
a signiﬁcant and concentration-related inhibition of MCP-1 amounts measured in the 
supernatants of stimulated cells treated with bindarit. It is well known that MCP-1 
activity is in part due to recruitment of monocytes/macrophages that are responsible 
for local production of cytokines, but MCP-1 may also directly induce SMC 
proliferation and migration through cell cycle proteins and intracellular proliferative 
signals (Selzmam et al., 2002; Parenti et al., 2004). Our results also showed that 
bindarit reduced monocytes/ macrophages recruitment in injured rat carotid arteries. 
The rat balloon angioplasty model could be considered ideal to study the 
proliferation of SMCs in vivo; however, it is not an ideal model for the study of 
monocytes/macrophages recruitment, considering the injury is performed in a non-
atherosclerotic arterial bed. (Reidy et al., 1992; Roque et al., 2000). It is well known 
that hypercholesterolaemia, a potent trigger of vessel wall inﬂammation in 
atherosclerosis, induces MCP-1 expression in SMCs and upregulates CCR2 in 
human monocytes, enhancing monocyte recruitment after arterial injury and thus 
mediates the exacerbation of neointimal growth (Yu et al., 1992; Han et al., 1998; 
Oguchi et al., 2000). In our experiments, no clear atherosclerotic lesions were 
detectable in the aortic root of mice 28 days after injury. However, we and others 
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have demonstrated that lymphocytes already reside into the adventitia of arterial 
wall of apoE-/- mice even before the onset atherosclerosis (Galkina et al., 2006; 
Maffia et al., 2007). In this light, the hyperlipidaemic mice tool represents a step 
forward to the rat balloon angioplasty model, allowing us to study the effect of 
bindarit in the contest of increased vascular inﬂammation. Our results clearly 
demonstrated that bindarit reduced neointimal formation by reducing proliferating 
rate and macrophage inﬁltration, effects associated with a reduced expression of 
MCP-1 in injured vessels. In hypercholesterolaemic rabbits, gene transfer of a 
plasmid coding for a mutant form of MCP-1 appeared to reduce neointimal 
formation after balloon injury, mainly inhibiting macrophage inﬁltration to the injured 
vessels. Similarly, in hypercholesterolaemic apoE-/- mice also deﬁcient in CCR2, 
neointimal lesions after wire injury of the carotid artery were diminished and showed 
a marked reduction in macrophage content compared with apoE-/-/CCR2+/+ mice 
(Schober et al., 2004). In conclusion, this study demonstrates that bindarit is 
effective in reducing neointimal formation both in a nonhyperlipidaemic animal 
model of vascular injury, mainly by a direct effect on SMC proliferation/migration, 
and in hyperlipidaemic animals by reducing macrophage inﬁltration. The exploitation 
of the chemokine system as a drug target in vascular pathology has relied mainly on 
the development of receptor antagonists and blocking antibodies (Charo and 
Taubman, 2004). However, the attempt to block chemokines and their receptors in 
humans is more complex (Perico et al., 2008). Here, we report the use of bindarit, 
an inhibitor of MCP-1 synthesis, as a potentially viable approach to control 
neointimal formation even if the clinical effects cannot be immediately predicted and 
further experiments, as well as clinical trials, will be necessary 
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4. MONOCYTE CHEMOTACTIC PROTEIN-3 INDUCES HUMAN 
CORONARY SMOOTH MUSCLE CELL PROLIFERATION 
Monocyte chemotactic protein-3 (MCP-3), also known as CCL7, belongs to 
the monocyte chemotactic protein (MCP) subfamily of CC chemokines. MCP-
3 plays a critical role in regulating the mobilization and recruitment 
of monocytes and macrophages to inflammatory sites (Tsou et al., 2007). It has 
potent eosinophil chemoattractant properties (Shang et al., 2002) and is involved in 
the bone marrow homing of human multiple myeloma cells (Broek et al., 2003). 
Several studies suggest that MCP-3 may also be involved in vascular pathologies 
such as atherosclerosis and restenosis. Oxidised low-density lipoprotein (LDL) 
induced expression of MCP-3 in human atherosclerotic plaques (Jang et al., 
2004). MCP-3 mRNA expression has also been induced in the carotid artery after 
balloon angioplasty and in cultured rat vascular smooth muscle cells (SMCs) by 
various stimuli, such as TNF-α (Wang et al., 2000). Furthermore, mouse 
aortic SMCs were found to participate in the formation of tertiary lymphoid 
tissue in atherosclerosis through an increase in chemokine mRNA levels, 
including MCP-3 (Lötzer et al., 2010). SMCs express receptors for CC chemokines 
such as chemokine receptor 1 (CCR1), CCR2, CCR3, and CCR5 (Hayes et al., 
1998; Kodali et al., 2004). MCP-3 acts through interaction with CCR1, CCR2, 
and CCR3, but appears to be an antagonist for CCR5 (Rollins, 1997; Blanpain et 
al., 1999). Interestingly, CCR2 is known to be shared with MCP-1 (Hayes et al., 
1998), which directly induces SMC proliferation (Selzman et al., 2002). Although all 
these data suggest the possibility that SMCs react to MCP-3, the effect of MCP-
3 on SMC activation has not yet been investigated.  
The aim of the current study was to evaluate the direct influence of MCP-
3 on human coronary artery SMC (CASMC) proliferation, which plays a critical role 
in neointimal formation during vascular injury. Furthermore we analysed the 
intracellular signalling pathways involved in MCP-3 induced CASMC proliferation . 
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4.1. Methods 
4.1.1 Cell culture 
Human CASMCs (lots 7F3272 and 16737; Lonza) were grown in Smooth 
Muscle Basal Medium (SmBM; Lonza) supplemented with 0.5 mg/mL hEGF, 
5 mg/mL insulin, 1 mg/mL hFGF, 50 mg/mL gentamicin/amphotericin-B, and 5% 
FBS, and used between passages 4 and 8 for all experiments. Before initiation of 
assays, to achieve cell quiescence, CASMCs in exponential growth were switched 
into SmBM supplemented with 0.1% FBS in the absence of growth factors for 48 h. 
4.1.2 Cell proliferation studies 
Cell proliferation was analysed via measurement of DNA synthesis by a 
colorimetric bromodeoxyuridine (BrdU) enzyme linked immunosorbent assay 
(ELISA) kit (Roche) according to the manufacturer's instructions. Briefly, CASMCs 
were seeded in 96 multi-well plates at a density of 5 × 103 cells/well. After 
quiescence induction, cells were stimulated with human MCP-3 (0.001–30 ng/mL; 
PeproTech) for 24 h and then incubated with 10 μM BrdU 16 h prior to analysis. 
Human TNF-α (30 ng/mL; R&D Systems) was used as the positive control. In some 
experiments, BrdU uptake in CASMCs stimulated with MCP-3 (0.3 ng/mL) was 
measured in the presence of anti-MCP-3 Ab (20 ng/mL, PeproTech), RS 102895 
(CCR2 antagonist, 0.06–6 μM, Sigma–Aldrich), U0126 (MEK1/2 inhibitor, 1 μM, 
Santa Cruz Biotechnology), or LY-294002 (phosphotidylinositol 3 kinase, IP3K 
inhibitor, 5 μM, Santa Cruz Biotechnology). BrdU uptake was also evaluated in 
TNF-α (30 ng/mL), IL-1β (1 ng/mL, PeproTtech), FBS (5%), or PDGF-BB 
(10 ng/mL, R&D Systems)-stimulated cells, respectively, with or without anti-MCP-3 
Ab (20 ng/mL). In a separate set of experiments, CASMC proliferation was also 
evaluated by directly counting the cell number using the trypan blue method. Briefly, 
CASMCs (1 × 105) were seeded in 25 cm2 cell culture flasks. After quiescence 
induction, cells were stimulated with MCP-3 (0.3 ng/mL) or TNF-α (30 ng/mL) for 
96 h. Cells were trypsinized, stained with trypan blue solution (0.4%, Sigma–
Aldrich), and counted by an independent observer blinded to the experiment. 
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4.1.3 Cytotoxicity assay 
The cytotoxicity assay was carried out using the MTT method. Briefly, 
CASMCs were plated in 48 multi-well plates at a density of 1.5 × 104 cells/well. After 
quiescence induction, cells were treated with RS 102895 (0.06–6 μM), U0126 (1–
100 μM), or LY-294002 (5–50 μM) for 24 h. The absorbance values were obtained 
with an ELISA assay reader (630 nm). 
4.1.4 Total cellular extracts 
CASMCs were cultured in 24 multi-well plates until 90% confluence. After 
quiescence induction, cells were stimulated with MCP-3 (0.3 ng/mL) or TNF-α 
(30 ng/mL). At different time points, cells were washed twice with ice cold PBS after 
which 30 μL/well of lysis buffer (50 mM Tris–HCl, 1% Triton, 1 mM Na3VO4, 1 mM 
ethylenediaminetetraacetic acid (EDTA), 0.2 mM phenylmethylsulfonyl fluoride 
(PMSF), 25 μg/mL Leupeptin, 10 μg/mL Aprotinin, 10 mM NaF, 150 mM NaCl, 
10 mM β-glycerophosphate, 5 mM pyrophosphate, and H2O) were added. Protein 
concentration was determined using a Bio-Rad protein assay kit (Bio-Rad). 
4.1.5 Western blot analysis 
Total cell lysates (20 μg) were separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose 
membranes (Millipore). Membranes from 3 experiments were incubated with anti-p-
ERK1/2 Ab (phosphorylated at Thr 202/Tyr 204, 1:2000, Cell Signaling), followed by 
stripping and reprobing with anti-ERK1/2 Ab (1:2000, Cell Signaling). Different 
membranes (n=3) were incubated with either (1) anti-p-AKT Ab (phosphorylated at 
Ser 473, 1:1000, Cell Signaling), followed by stripping and reprobing with anti-AKT 
Ab (1:1000, Cell Signaling); (2) anti-p-p70 S6K Ab (phosphorylated at Ser 411, 
1:1000, Santa Cruz Biotechnology), followed by stripping and reprobing with anti-β-
actin Ab (1:5000, Sigma–Aldrich); or (3) anti-IκB-α Ab (1:1000, Santa Cruz 
Biotechnology), followed by stripping and reprobing with anti-β-actin Ab (1:5000, 
Sigma–Aldrich). The membranes were washed three times with 0.5% Triton in PBS 
and then incubated with anti-rabbit or anti-mouse immunoglobulins coupled to 
peroxidase (1:1000, DAKO). The immunocomplexes were visualised by the ECL 
chemiluminescence method. ERK 1/2 activity is expressed as the ratio of 
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phosphorylated ERK 1/2 to total ERK 1/2; AKT as the ratio of phosphorylated AKT 
to total AKT; p70 S6K as the ratio of phosphorylated p70 S6K to β-actin; and IκB-α 
as the ratio of IκB-α to β-actin. 
4.1.6 Electrophoretic mobility shift assay (EMSA) 
Double stranded nuclear factor (NF)-κB consensus oligonucleotide probe (5′ 
AGC TTC AGA GGG GAC TTT CCG AGA GG 3′) was end-labeled with [32P]γ-ATP. 
Cellular extracts (5 μg protein per sample) were incubated for 30 min with 
radiolabeled oligonucleotides (2.5–5.0 × 104 cpm) in 20 μL reaction buffer 
containing 3 μg poly dI-dC, 10 mM Tris–HCl (pH 7.5), 100 mM NaCl, 1 mM EDTA, 
1 mM dithiothreitol, 1 μg/μL bovine serum albumin, and 10% (v/v) glycerol. Protein–
oligonucleotide complexes were resolved by electrophoresis on a 6% non-
denaturing polyacrylamide gel in 1× Tris–borate/EDTA at 180 V for 2 h at 4 °C. The 
gels were dried and autoradiographed with intensifying screens at −80 °C for 24 h.  
4.1.7 Enzyme linked immunosorbent assay (ELISA) 
CASMCs were seeded in 48 multi-well plates at a density of 
1.5 × 104 cells/well. After quiescence induction, cells were stimulated with TNF-α 
(30 ng/mL), IL-1β (1 ng/mL), PDGF-BB (10 ng/mL), or FBS (5%). After 12, 24, and 
48 h, media were collected and centrifuged at 5000 × g for 15 min at 4 °C. The 
supernatants extracted were immediately frozen at −80 °C until use. MCP-3 levels 
in the cell supernatants were evaluated by ELISA according to the manufacturer's 
instructions (R&D Systems). 
4.1.8 Statistical analysis 
Results are expressed as mean±SEM of n experiments run in triplicate. The 
results were statistically analysed by the t test or ANOVA (Two-Tail P value) and the 
Bonferroni post hoc test. The level of statistical significance was 0.05 per test. 
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4.2 Results 
4.2.1 Effect of MCP-3 on coronary artery smooth muscle cell (CASMC) proliferation 
To assess the effect of MCP-3 on CASMC proliferation we performed, 
concentration–response experiments using BrdU uptake as a marker of DNA 
synthesis. TNF-α (30 ng/mL) was chosen as the positive control owing to its well-
known mitogenic effect on SMCs. When CASMCs were stimulated with increasing 
concentrations of MCP-3 (0.001–0.3 ng/mL), a concentration-dependent 
proliferation was observed (Fig. 4.1A). MCP-3, which was ineffective at 
0.001 ng/mL, showed moderate increase of CASMC proliferation at 0.01 and 
0.03 ng/mL of 12% (n=7) and 24% (n=7), respectively, and significant increase of 
CASMC proliferation at 0.1 ng/mL of 36% (P<0.05, n=7). The maximum stimulating 
effect, which was observed at 0.3 ng/mL, was 55% (P<0.001, n=7) compared to 
unstimulated cells. CASMC proliferation induced by 1 ng/mL MCP-3 showed a slight 
decrease compared to 0.3 ng/mL (38%,P<0.05, n=7). MCP-3 at concentrations 
ranging from 3 to 30 ng/mL induced no significant changes in CASMC proliferation 
(Fig. 4.1A). TNF-α (30 ng/mL) significantly increased CASMC proliferation by 62% 
(P<0.001, n=7) (Fig. 4.1A). We also evaluated CASMC proliferation by directly 
counting the cells in 25 cm2 flasks (Fig. 4.1B). The CASMC number significantly 
increased at 96 h after stimulation with MCP-3 (0.3 ng/mL) 
(20.6 × 104±2 × 104, P<0.05, n=3) when compared to unstimulated cells 
(13.8 × 104±1 × 104, n=3). The number of CASMCs counted 96 h after stimulation 
with 30 ng/mL TNF-α was 21.0 × 104±1.1 × 104 (n=3). 
To demonstrate the specificity of the MCP-3 stimulation, BrdU uptake was 
measured in the presence of anti-MCP-3 Ab (20 ng/mL), which completely inhibited 
the proliferation induced by MCP-3 (0.3 ng/mL, P<0.001, n=5) (Fig. 4. 1C). 
BrdU uptake was also measured in the presence of RS 102895, a specific 
antagonist of the CCR2 receptor (Ma et al., 2007), to investigate its involvement in 
MCP-3-induced CASMC proliferation. As shown in Figure 4.1D, RS 102895 at 
0.06 μM moderately reduced MCP-3 (0.3 ng/mL)-induced CASMC proliferation by 
38% (n=4), whereas at 0.6 and 6 μM induced significant inhibition of cell 
proliferation by 64% (P<0.05, n=4) and 88% (P<0.01, n=4), respectively. RS 
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102895 alone, at the concentrations used, did not affect CASMC proliferation (Fig. 
4.1D). 
 
 
Figure 4.1.  
Effect of MCP-3 (0.001-30 ng/mL) on CASMC proliferation assessed by BrdU incorporation (A) and 
by cell counting expressed as total cells number (B). Effects of neutralizing anti-MCP-3 Ab (20 
ng/mL), and RS 102895 (0.06-6 µM) on MCP-3-induced CASMC proliferation (C, D). TNF-α (30 
ng/mL) was used as positive control. Results are expressed as mean±SEM of three to seven 
separate experiments run in triplicate. *P<0.05, **P<0.01, ***P<0.001 vs unstimulated cells; °P<0.05, 
°°P<0.01, °°°P<0.001 vs MCP-3-stimulated cells. 
4.2.2 Effect of MCP-3 on ERK1/2 and AKT/p70 S6K activation in coronary artery 
smooth muscle cells (CASMCs) 
We tested the hypothesis that MCP-3-induced CASMC proliferation is 
associated with ERK1/2 and AKT–mTOR-p70 activation since these two signalling 
pathways are the major regulators of cell growth and proliferation (Peppel et al., 
2005; Duan et al., 2000; Stabile et al., 2003; Brito et al., 2009). CASMCs were 
stimulated with MCP-3 (0.3 ng/mL) or TNF-α (30 ng/mL), used as the positive 
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control. Western blot analysis shows that ERK activation, visible as an increase of 
phosphorylation of p44 and p42 proteins, occurred in MCP-3-stimulated CASMCs 
within 5 min (32% vs unstimulated cells) and returned to basal levels after 15 min 
(Fig. 4.2A). As shown in Figure 4.2B and 4.2C, MCP-3 also enhanced AKT and p70 
S6K phosphorylation. In both cases the peak of phosphorylation was observed 
within 5 min (40% and 53% vs unstimulated cells, respectively). 
4.2.3 Effect of MCP-3 on NF-κB activation in coronary artery smooth muscle cells 
(CASMCs) 
Since the NF-κB pathway is also involved in SMC proliferation, we 
investigated NF-κB activation in CASMCs stimulated with MCP-3 (0.3 ng/mL) or 
TNF-α (30 ng/mL), used as the positive control. TNF-α, as expected, induced 
significant and time-dependent IκB-α degradation (Fig. 4.3A) and strong NF-κB 
activation as evaluated by EMSA at 4 h after stimulation (Fig. 4.3B). In contrast, 
MCP-3 showed no effect on NF-κB activation (Fig. 4.3A and B). 
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Figure 4.2.  
Representative Western Blot and relative densitometric analysis showing the effects of MCP-3 (0.3 
ng/mL) and TNF-α (30 ng/mL), used as positive control, on ERK 1/2 (A), AKT (B) and p70 S6K (C) 
activation in CASMCs. Results are expressed as mean±SEM from three separate experiments. 
*P<0.05, **P<0.01, ***P<0.001 vs unstimulated cells. 
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Figure 4.3.  
Representative Western Blot and relative densitometric analysis showing the effect of MCP-3 (0.3 
ng/mL) and TNF-α (30 ng/mL), used as positive control, on IκBα degradation in CASMCs (A). 
Representative EMSA showing the effect of MCP-3 (0.3 ng/mL) and TNF-α (30 ng/mL), on NF-κB 
activation (B). Results are expressed as mean±SEM of three separate experiments. ***P<0.001 vs 
unstimulated cells. 
4.2.4 Effect of inhibition of ERK 1/2 and IP3K activation on MCP-3-induced coronary 
artery smooth muscle cell (CASMC) proliferation 
To confirm the involvement of the ERK 1/2 and IP3K signalling pathways in 
MCP-3-induced CASMC proliferation, cells were stimulated with MCP-3 (0.3 ng/mL) 
in the presence of U0126, an inhibitor of MEK 1/2 (MAPK of ERK kinases) (Yao et 
al., 2008) or LY-294002, a selective inhibitor of IP3K (Walcher, et al., 2006), 
followed by BrdU uptake measurement. As shown in Figure 4.4, U0126 (1 μM) and 
LY-294002 (5 μM) significantly reduced MCP-3-induced CASMC proliferation by 
36% (P<0.05, n=3) and 64% (P<0.01, n=3), respectively. Neither U0126 nor LY-
294002 alone affected CASMC proliferation (Fig. 4.4). 
71 
 
 
Figure 4.4.  
Effect of U0126 (1 μM) and LY-294002 (5 µM) on MCP-3 (0.3 ng/mL)-induced CASMC proliferation. 
Results are expressed as mean±SEM from three separate experiments run in triplicate. **P<0.01 vs 
unstimulated cells; °P<0.05 and °°P<0.01 vs MCP-3-stimulated cells. 
4.2.5 Evaluation of MCP-3 production by coronary artery smooth muscle cells 
(CASMCs) 
To investigate the pathophysiological role of MCP-3, CASMCs were 
stimulated with different stimuli such as TNF-α (30 ng/mL), IL-1β (1 ng/mL), PDGF-
BB (10 ng/mL), or FBS (5%). MCP-3 protein concentration in the supernatants of 
cultured CASMCs was determined by ELISA. As shown in Table 4.1, stimulation of 
CASMCs with TNF-α (30 ng/mL) or IL-1β (1 ng/mL) caused a time-dependent 
increased release of MCP-3 compared to that observed in unstimulated cells. In 
contrast, neither PDGF-BB (10 ng/mL) nor FBS (5%) affected MCP-3 production. 
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Table 4.1 MCP-3 production by stimulated CASMCs 
 MCP-3 (pg/mL) 
12h 24h 48h 
    
Unstimulated cells 38435 60225 97177 
TNF-α 30 ng/mL 107754°°° 1805167°°° 3636235°°° 
IL-1β 1 ng/mL 85082° 115747° 2702283°°° 
PDGF-BB 10 ng/mL 581133 71675 117156 
5% FBS 39137 731141 1469112 
Results are expressed as meanSEM of three separate experiments run in triplicate. °P<0.05, 
°°°P<0.001 vs unstimulated cells. 
 
 
4.2.6 Effect of MCP-3 neutralization on coronary artery smooth muscle cell 
(CASMC) proliferation 
To further investigate the pathophysiological role of MCP-3 production by 
CASMCs, we also evaluated the effect of MCP-3 neutralization on cell proliferation 
induced by TNF-α (30 ng/mL), IL-1β (1 ng/mL), PDGF-BB (10 ng/mL), and FBS 
(5%), respectively. Treatment with anti-MCP-3 Ab (20 ng/mL) significantly reduced 
the proliferation induced by TNF-α (79% vs unstimulated cells) and IL-1β 
(58% vs unstimulated cells) by about 12% (P<0.01, n=3) and 14% (P<0.05, n=3), 
respectively, while no effect was observed in PDGF-BB- or FBS-stimulated 
CASMCs (Fig. 4.5). 
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Figure 4.5  
Effect of anti-MCP-3 neutralizing Ab on CASMC proliferation induced by  TNF-α (30 ng/mL), IL-1β (1 
ng/mL), PDGF-BB (10 ng/mL) and FBS (5%). Results are expressed as mean±SEM from five 
separate experiments run in triplicate. °° P<0.01 vs unstimulated cells, **P<0.01 vs TNF-α-stimulated 
cells, *P<0.05 vs IL-1β-stimulated cells.  
4.3 Discussion 
MCP-3 exhibits biological activity in various cell types (Tsou et al., 2007; 
Shang et al., 2002; Broek et al., 2003), however, previously nothing was known 
about its direct influence on SMC activation and the intracellular signalling pathways 
involved. In the present study, we demonstrate that human MCP-3 directly 
promotes in vitro proliferation of human CASMCs, at least in part, through the 
activation of the ERK1/2 MAPK and PI3K signalling pathways. We also demonstrate 
that MCP-3 is produced by CASMCs, and that its inhibition by anti-MCP-3 Ab 
reduces cell proliferation induced by both TNF-α and IL-1β. 
To better identify the proliferative activity of MCP-3, we analysed a large 
concentration–response range. Our results show that MCP-3 induced 
concentration-dependent CASMC proliferation up to 0.3 ng/mL, while higher 
concentrations of MCP-3 (3–30 ng/mL) did not cause any significant increase of cell 
proliferation. This bimodal proliferative response of MCP-3-stimulated CASMCs was 
similar to that observed by Selzman et al. (Selzman et al., 2002) for MCP-1 in 
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human thoracic SMCs, and is a typical finding for a chemotactic response to CC 
chemokines (Haque et al., 2004). A possible explanation for this is that activation of 
more than one receptor could be involved in the proliferation process. Indeed, MCP-
3 exhibits a promiscuous nature of receptor recognition, being an agonist on CCR1, 
CCR2, and CCR3, while an antagonist for CCR5 (Rollins, 1997; Blanpain et al., 
1999). 
We studied a number of different mechanisms for MCP-3-induced CASMC 
proliferation. The involvement of the ERK1/2 MAPK cascade and PI3K/AKT 
signalling pathway in SMC proliferation has previously been demonstrated (Peppel 
et al., 2005; Duan et al., 2000; Stabile et al., 2003). It has also been shown that the 
ERK1/2 pathway is involved in MCP-3-mediated chemotaxis of peripheral blood 
mononuclear cells (Wain et al., 2001), and that ERK1/2 inactivation prevents intimal 
hyperplasia after balloon angioplasty of rat carotid artery (Izumi et al., 2001), a well-
known animal model for studying proliferation of SMCs in vivo. In previous studies, 
it was shown that SMC proliferation is also regulated by PI3K/AKT signalling (Duan 
et al., 2000; Stabile et al., 2003). The activation of this pathway in different cell 
types, such as fibroblasts, is induced by MCP-3 stimulation (Ong et al., 2009). 
Results from the present study show an increase of ERK1/2 and AKT 
phosphorylation in MCP-3-stimulated CASMCs. Moreover, the selective inhibition of 
MEK1/2 (MAPK of ERK kinases) by U0126 and the inhibition of PI3K by LY-294002 
significantly reduced MCP-3-induced CASMC proliferation. It is well established that 
SMC proliferation is also influenced by NF-κB activation. However, our results show 
that MCP-3 affects neither IκB-α degradation nor NF-κB activation. These data, 
taken together, clearly demonstrate that MCP-3-induced CASMC proliferation is 
partially dependent on ERK1/2 and PI3K activation, without direct involvement of 
the NF-κB pathway. 
The induction of cultured human SMC proliferation by MCP-3, demonstrated 
here, and the increased MCP-3 mRNA expression in rat carotid artery after balloon 
angioplasty (Wang et al., 2000) suggest a potential role of this chemokine in intimal 
hyperplasia. To better clarify this point, we measured the MCP-3 production in 
CASMCs stimulated with TNF-α, IL-1β, or PDGF-BB, which are known to be 
involved in intimal hyperplasia (Peppel et al., 2005; Isoda et al., 2003). We 
observed time-dependent increase of MCP-3 production in the IL-1β- and TNF-α-
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stimulated CASMCs. Moreover, treatment with anti-MCP-3 Ab significantly reduced 
the proliferation induced by these mediators. Our results demonstrate that in 
vitro MCP-3 can act in a paracrine/autocrine way, promoting SMC proliferation. 
Jang et al. (Jang et al., 2004) observed expression of MCP-3 in foam cells but not in 
SMCs in human atherosclerotic plaques. This lack of MCP-3 production in SMCs 
could be due to the different experimental approaches. Nevertheless, MCP-3 
produced in the vessel wall by macrophages and/or SMCs could be a potential 
mediator for inflammatory and proliferative cellular responses. To elucidate the role 
of MCP-3 in intimal hyperplasia, future investigations in vivo are necessary. 
The initiation and development of atherosclerosis and intimal hyperplasia 
after vascular injury is regulated by the MCP-1/CCR2 pathway (Boring et al., 1998; 
Egashira et al., 2002). There is strong evidence that MCP-1/CCR2 plays an 
important role in SMC proliferation and migration (Selzman et al., 2002). The CCR2 
receptor is known to be shared with MCP-3 and is expressed on human 
SMCs (Hayes et al., 1998). Our results show that the proliferative effect of MCP-3 is 
due to its interaction with CCR2, as demonstrated by the reduction of the effect 
when using the selective antagonist RS 102895. It is interesting to note that 
CCR2−/− mice have a ≈60% decrease in intimal hyperplasia and medial DNA 
synthesis in response to femoral arterial injury while MCP-1−/− mice show a ≈30% 
reduction in intimal hyperplasia, which is not associated with diminished medial 
DNA synthesis (Kim et al., 2003), suggesting that MCP-1 and CCR2 deficiencies 
have distinct and separate effects on arterial injury. Therefore, it is possible that the 
results obtained with CCR2−/− mice may not be solely mediated by MCP-1 but also 
by other chemokines such as MCP-3. 
In conclusion, our results demonstrate that MCP-3 is produced by human 
CASMCs and directly induces SMC proliferation in vitro via ERK and PIK3 
activation. Therefore, MCP-3 could play a role in the molecular cascades leading to 
neointimal hyperplasia. 
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5. MURINE VASCULAR SMOOTH MUSCLE CELLS DO NOT 
PRESENT ANTIGEN AND LACK ESSENTIAL COSTIMULATORY 
MOLECULES 
Inflammation and immunity are essential components of the pathogenesis of 
cardiovascular diseases (Libby, 2002; Hansson et al., 2002), participating in every 
phase during the development of atherosclerosis (Hansson and Libby, 2006). 
Activation of SMCs has a critical role in intimal thickening resulting from 
atherosclerosis or arterial injury (Owens et al., 2004) and, during the past 20 years, 
the hypothesis that SMCs could play a proimmunogenic role in cardiovascular 
disease has been explored. Indeed, SMCs participate in the formation of vascular 
tertiary lymphoid tissue in atherosclerosis (Lötzer et al., 2010) and express class II 
major histocompatibility complex molecules (MHC II) in the human atherosclerotic 
plaque (Hansson et al., 1986). Expression of MHC II has also been shown in vivo 
after ballon-induced rat arterial injury and in vitro after stimulation of aortic SMCs 
with IFN-γ (Hansson and Jonasson, 2009).  
It is well known that T cells, resident in normal arteries or infiltrating diseased 
arteries, recognize antigens as a complex formed by antigenic peptides bound to 
self allelic forms of MHC molecules expressed on the surface of antigen-presenting 
cells (APC). The possibility that SMCs can act as APC and, consequently, activate 
T cell response is now disputed.  It has been demonstrated that brain microvessel 
SMCs treated with OVA antigen are able to activate A2.2E10 cells, an OVA-specific 
T cell hybridoma (Fabry et al., 1990). However, human SMCs from saphenous vein 
do not activate allogeneic memory T cells and fail to effectively support T-cell 
proliferation to the polyclonal activator, phytohemagglutinin. This inability results 
from a defect  in costimulation function, particularly the lack of essential 
costimulators such as OX40 ligand (OX40L) (Zhan et al., 2010). Up to now the 
effective ability of SMCs in capturing, processing and presenting the antigen in the 
context of MHC II has not yet been demonstrated. 
The aim of the present study was to investigate the contribution of SMCs in 
antigen presentation to better understand their role in vascular immunity. These 
experiments were performed in the Institute of Infection, Immunity and Inflammation 
University of Glasgow, UK. 
77 
 
5.1 Methods 
5.1.1 Cell culture 
 Murine primary SMCs were derived from the thoracic aorta of C57BL/6 mice 
as previously described (Choi et al., 2004) and grown in DMEM (Cambrex Bio 
Sciences), supplemented with L-glutamine (Cambrex Bio Sciences), 10% fetal 
bovine serum (FBS, Cambrex Bio Sciences), 100 U/mL penicillin, and 100 µg/mL 
streptomycin. Before initiation of assay the cells were characterized by 
immunofluorescence microscopy using FITC labeled anti-smooth muscle α-actin (α-
SMA) monoclonal Ab (Sigma). Studies were performed with cells at passages 3-6. 
Dendritic cells (DCs) were obtained by flushing the bone marrow of C57BL/6 mice 
and grown in complete RPMI (Cambrex Bio Sciences) containing 10% Granulocyte-
Macrophage Colony Stimulating Factor (GM-CSF) for 7 days. All cells used were 
kept in a humidified incubator at 37°C in 5% CO2. 
5.1.2 MHC II and costimulatory molecules expression 
Murine SMCs were cultured in 6 multi-well plates until 80% confluence and 
stimulated with IFN-γ (100 ng/ml, R&D Systems). After 72 h of stimulation cells 
were collected for flow cytometric analysis. 
5.1.3 Ealpha-GFP preparation 
To assess the ability of murine SMCs to act as APC, we employed the 
Ealpha (Eα)-GFP/Y-Ae system as previously described (Itano et al., 2003). The 
peptide was prepared as follows: bacterial E.Coli culture, that espressed the Eα-
GFP gene, were used. Protein production was induced with 1 mM Isopropil β-D-1-
tiogalattopiranoside (IPTG) overnight, and the Eα-GFP fusion protein was purified 
from the bacterial lysates using HisPur Cobalt Spin Columns (Thermo Scientific). 
The endotoxin was removed from protein preparation using Detoxi-Gel Endotoxin 
Removing Columns (Thermo Scientific). 
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5.1.4 Ealpha-GFP treatment 
Murine SMCs were cultured in 6 multi-well plates, as described above, 
stimulated with IFN-γ (100 ng/ml) for 72 h, then treated with Eα-GFP (100 µg/mL). 
After 24 h of treatment cells were collected for flow cytometric analysis.  
5.1.5 Flow Cytometry 
Aliquots of cells were washed and resuspended in Fc block (2.4G2 
hybridoma supernatant) for 25 mins at 4°C to block Fc receptors. Subsequently, 
cells were incubated with Abs (in PBS containing 2% FBS) for 30 mins at 4°C, 
washed twice and then, where necessary, incubated with Streptavidin for additional 
20 mins at 4°C. Following washing, cells were analysed on a FACScalibur using the 
CellQuest-Pro software (BD Biosciences), or on a MACSQuant Analyzer® using 
the MACSQuantify™ Software (Miltenyi Biotec). Fluorescence signals were 
accumulated as two-parameter fluorescence histograms with the percent positive 
cells being recorded and data analysis was performed using 6 FlowJo (Tree Star 
Inc.).  
Murine SMCs were stained with the following primary mouse (m) Abs: Y-Ae-
Bio (specific for I-Eα 52-68 of I-Ed presented on I-Ab; ebioY-Ae), anti-MHC II (I-A/I-
E)-APC, anti-CD54-PE, anti-CD44-FITC, anti-OX40L-Bio followed by streptavidin-
PerCP. Dendritic cells were stained with anti-CD11c-APC mAb. Isotype-matched 
Abs were used as a negative control. Y-Ae Ab was from eBioscience, Streptavidin-
Pacific Blue was from Invitrogen, all other Abs were from BD Biosciences. 
5.1.6 Statistical analysis  
Results are expressed as mean±SEM of 3 experiments run in triplicate. The 
results were statistically analysed by ANOVA (Two-Tail P value) and the Bonferroni 
post hoc test. The level of statistical significance was 0.05 per test. 
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5.2 Results 
5.2.1 Effect of IFN-γ stimulation on MHC II and costimulatory molecules expression 
in murine SMCs 
We examined the MHC II and some costimulatory molecules expression in 
murine SMCs at baseline and after IFN-γ (100 ng/mL) stimulation for 72 h.  
As shown in Figure 5.1, the percentage of MHC II positive unstimulated 
SMCs was about 2%. The stimulation with IFN-γ significantly caused a 7 to 8 fold 
increase in this percentage (P<0.01). SMCs expressed CD54 (ICAM-1) and CD44 
(30% and 87% positive cells, respectively) at the basal conditions. The stimulation 
with IFN-γ significantly caused a 2 fold increase in the percentage of ICAM-1 
(P<0.01) positive cells while it did not affect the expression of CD44 (Fig. 5.1). In 
contrast, low levels of OX40L expression were detectable in unstimulated SMCs. 
IFN-γ stimulation did not increase the percentage of SMCs positive to this molecule 
(Fig. 5.1). 
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Figure 5.1 
Representative flow cytometry histograms and relative graph showing the effect of IFN-γ (100 
ng/mL) on costimulatory molecules expression in murine SMCs. Black empty histograms or black 
columns (IFN-γ-stimulated cells) vs gray filled histograms or white columns (unstimulated cells). 
Results are expressed as mean±SEM from three separate experiments. *P<0.05, **P<0.01, vs 
unstimulated cells. 
5.2.2 Assessment of antigen presentation by SMCs using the Eα-GFP/Y-Ae system 
Recent investigations suggest that SMCs can induce T cell activation in vitro. 
However, it is not known if vascular SMCs can function as antigen presenting cells. 
We utilized the Eα-GFP/Y-Ae model, recently established in Prof. Garside‘s group 
(University of Glasgow, UK), that allows visualisation of antigen uptake, as the Eα is 
GFP labelled, and tracking of antigen presentation using the Y-Ae Ab. The Eα-GFP 
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peptide is internalised, processed by APCs to generate the antigenic peptide for 
presentation on MHC II. The monoclonal Ab Y-Ae detects Eα when bound to MHC 
II molecules in I-E-/I-Ab+ mouse strains (e.g. C57BL/6). 
The stimulation with IFN-γ (100 ng/mL) for 72 h significantly caused a 5 to 6 
fold increase in the percentage of MHC II positive SMCs compared with 
unstimulated cells (P<0.01, Fig. 5.2A). Similar results were observed in IFN-γ-
stimulated SMCs treated with Eα peptide (100 µg/mL) for 24 h (P<0.05, Fig. 5.2A). 
As shown in Figure 5.2 B, SMC treatment with Eα peptide induced an increase in 
the percentage of GFP positive cells, both in presence or absence of IFN-γ-
stimulation, being indicative of antigen uptake. No significant changes were 
observed in the percentage of Y-Ae positive SMCs after IFN-γ-stimulation and/or 
treatment with Eα peptide (Fig. 5.2C), suggesting that, although SMCs internalize 
the antigen, they are not able to present the Eα peptide in the context of MHC II 
molecules. The results obtained with dendritic cells, used as positive control, 
showed that the treatment with Eα peptide for 24 h significantly caused a 50 to 60 
fold increase in the percentage of both GFP and Y-Ae positive cells (data not 
shown).  
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Figure 5.2  
Evaluation of antigen presentation by murine SMCs. Cells were stimulated with IFN-γ (100 ng/mL) 
for 72 h and treated with Eα-GFP peptide (100 µg/mL) for 24 h. (A) MHC II expression. (B) GFP 
expression. (C) Representative flow cytometry plots showing no positivity of SMCs to Y-Ae Ab. 
Results are expressed as mean±SEM from three separate experiments. *P<0.05, **P<0.01, vs 
unstimulated cells. 
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5.3 Discussion 
The finding of this study is that cultured primary murine SMCs express MHC 
II molecules after stimulation with IFN-γ but are not able to present the antigen in 
the context of MHC II.  
It is now generally accepted that atherosclerosis is an inflammatory process 
with an immune component. The first findings that SMCs espress MHC II molecules 
both during atherosclerosis (Hansson et al., 1986) and arterial response to injury 
(Jonasson et al., 1988) suggested their active role in cellular immunity. Previous 
studies have reported that human SMCs, do not activate allogeneic CD4 T cells in 
co-culture although once T cells are activated by endothelial cells, they are capable 
of responding to SMCs from the same donor (Murray et al., 1995). Zhang et al 
demonstrated that lack of costimulation function of human SMCs contributes to their 
immunologic ignorance (Zhang et al., 2010) but they hypothesized that their 
conclusions may not apply to rodents, as it has been reported that brain murine 
SMCs activate CD4 T-cell cytokine production and proliferation (Fabry et al., 1993; 
Swanson et al., 2003). Although SMCs in certain experimental condition can 
activate T cells, it has not been directly demonstrated that SMCs can act as APC. 
Here we investigated the costimulatory molecules expression in murine aortic 
SMCs and the capability of SMCs in antigen presentation, using a direct and 
specific method: the Eα-GFP/Y-Ae system. In agreement with the data obtained on 
human SMCs by Zhang et al (Zhang et al., 2010), our results show that murine 
SMCs do not express OX40L, usually present on APC enabling T cell activation 
(Maizels and Yazdanbakhsh, 2003) neither in absence nor in presence of IFN-γ. 
The failure of SMCs to respond to IFN-γ in our assays is selective for the 
costimulatory molecule because the percentage of MHC II and ICAM-1 positive 
cells increases after IFN-γ stimulation under the same conditions. In this study we 
also demonstrate that after 24 h of treatment with the Eα peptide, SMCs internalize 
the antigen without presenting it. 
The data obtained in this study must be considered preliminary, since it could 
be possible that SMCs require a more long period of treatment to be able in 
processing/presenting the peptide, thus a time course of the potential antigen 
presentation by SMCs should be examined. Moreover, the expression of other 
costimulatory molecules will be analysed.  
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Although our data suggest that SMCs are not able to present the antigen, 
they could have other critical roles in T cell activation. In order to investigate this 
issue we will co-culture SMCs, treated with different antigens, with specific T cell 
lines, some of them can be activated by APC without any requirement for co-
stimulation, and T cell activation/proliferation will be evaluated. 
85 
 
6. CONCLUSIONS 
Restenosis is the most problematic complication of percutaneous coronary 
intervention. Evidences from experimental and clinical studies suggest that at the 
base of this process there is an immune/inflammatory response going with a 
hyperplastic reaction involving SMC migration/proliferation and remodelling of the 
arterial wall leading finally to the reocclusion of the enlarged artery (Welt and 
Rogers, 2002). Many of the cellular and molecular elements responsible for 
inflammation and/or SMC activation have been elucidated, providing potential 
therapeutic targets for the treatment of restenosis.  
It is well known that the transcriptional factor NF-κB plays a critical role in the 
vascular response to injury (Yamasaki et al., 2003) regulating both inflammatory 
response and proliferation-apoptosis balance in the vessel wall (De Winther et al., 
2005). The identification and characterization of the NBD peptide, which blocks the 
IKK complex, essential for NF-κB pathway activation, have provided an opportunity 
to selectively abrogate the inflammation-induced activation of NF-κB. In this study 
we demonstrated that the NBD peptide reduces neointimal formation and SMC 
proliferation/migration, both effects associated with the inhibition of NF-κB activation 
and with the decrease of MCP-1 production, which role in vascular disease has 
been well described. Our results confirm the involvement of NF-κB as a regulator in 
the formation of neointima and support the use of specific IKK inhibitors to reduce 
neointimal hyperplasia. 
The increasing appreciation of the importance of inflammation in vascular 
disease has focused attention on the molecules that direct the migration of 
leukocytes from the blood stream to the vessel wall. Recently particular attention 
has been received by chemokines, a family of proteins which genes are under the 
control of NF-κB (Landry et al., 1997). Chemokines selectively recruit monocytes, 
neutrophils, and lymphocytes to sites of vascular injury, inflammation or 
atherosclerosis and some of them seem also to be involved in SMC activation  
(Schober, 2008). MCP-1, acting through its receptor CCR2, appears to play an 
important role in the formation of intimal hyperplasia after arterial injury, being 
involved in both leukocyte recruitment and SMC activation (Charo and Taubman, 
2004). Studies in different animal models suggest that an anti-inflammatory 
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treatment, based on the inhibition of MCP-1, may be an appropriate and reasonable 
approach for the prevention of neointimal formation (Furukawa et al., 1999; 
Egashira et al., 2007; Nakano et al., 2007). Nevertheless, the possibility to use an 
oral inhibitor of MCP-1 pathway, has not yet been investigated. Here we evaluated 
the effect of bindarit, a selective inhibitor of the MCPs subfamily (including MCP-1, 
MCP-2 and MCP-3) in neointimal formation in both non-hyperlipidaemic and 
hyperlipidaemic animal models of vascular injury. The results provided in this study 
demostrate that bindarit is effective in reducing neointimal formation through a direct 
effect on SMC proliferation and migration and macrophage recruitment, thus 
supporting its beneficial effect on the inflammatory/proliferative processes leading to 
neointimal formation.  
During the past few years we have witnessed a rapid increase in our 
understanding of the role of chemokines and their receptors in cardiovascular 
pathologies. Nevertheless, the precise mechanism of the chemokine pathways 
involved in the response of the arterial wall to injury is not fully elucidated. As told 
above,  it is known that chemokines have a great impact on initiating and 
progressing neointimal formation by controlling each step of the vascular obstructive 
remodelling process. Indeed, they can direct inflammatory cell recruitment, 
endothelial regeneration as well as SMC accumulation (Schober, 2008). Several 
studies suggest that, apart MCP-1, other chemokines, belonging to the same family, 
may be involved in vascular pathology (Wang et al., 2000). Our attention has been 
focused on MCP-3, that we consider very interesting since it acts through 
interaction with the receptors CCR1, CCR2 and CCR3 (Rollins, 1997; Blanpain et 
al., 1999), all expressed by vascular SMCs (Hayes et al., 1998; Kodali et al., 2004). 
It is known that CCR2 is shared with MCP-1, thus MCP-3 could have a role in SMC 
activation just like MCP-1 (Selzman et al., 2002). Here we demonstrate that MCP-3 
is produced by human coronary SMCs and directly induces cell proliferation in vitro, 
suggesting a potential role for this chemokine in vascular pathology and supporting 
the potential benefit of antichemokine strategies in this sense. 
The exploitation of the chemokine system as a drug target in vascular 
pathology has relied mainly on the development of receptor antagonists and 
blocking antibodies (Charo and Taubman, 2004). In addition, other antichemokine 
strategies may be feasible by locally confined delivery: blockers of signal 
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transduction, siRNAs or transcription factor inhibitors. As shown in this study, these 
approaches could be used to reduce chemokine activity or expression, combining 
the decreased inflammation with the lowered SMC activation, in an effort to control 
the neointimal hyperplasia. It is clear that further studies are needed before 
transcription factor- or chemokine-based therapies can be applied in clinical 
practice: valuable prognostic and therapeutic information must be acquired to be 
incorporated into the development of antirestenotic therapy. 
In the drug-eluting stent era it is interesting to note that some of 
immunosuppressive agents, currently used in therapy, have known inhibitory effect 
on regulatory elements of the cell cycle as well as on chemokines production. For 
example, in a porcine model of stent injury, sirolimus coated stents, are associated 
with reduced vessel wall protein expression of MCP-1 (Welt and Rogers, 2002). 
Anyway, the benefits of immunosuppressive current therapy are to be well 
elucidated, since the role of immunity in vascular response to injury remains still 
unclear. 
Recently it has been explored the hypothesis that SMCs could play a 
proimmunogenic role in cardiovascular disease (Murray et al.,1995; Swanson et 
al.,2003). The understanding of this issue could open the perspective to identify 
drugs having effect on both immunological and proliferative processes regarding 
SMC activation. Working in this direction, we investigate the contribution of SMCs in 
antigen presentation in vitro. Our results suggest that murine SMCs express MHC II 
molecules after stimulation with IFN-γ but they do not present the antigen in the 
context of MHC II. Because MHC II are usually expressed on APC, however, we 
hypothesize that SMCs could have other roles in T cell activation. Further 
investigations will be carry on to understand if SMCs are capable of participating in, 
and/or initiating an immune response during vascular pathology. 
Our findings and the evolving understanding of the pathogenesis of 
restenosis motivate major efforts on multiple fronts to fight cardiovascular disease, 
with the desirable goals of prevention as well as improved therapy. 
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